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Abstract 
 
 
Reprogramming Pediatric Genetic Disorders:  
Pearson Syndrome, Ring 14 Syndrome, and Fanconi Anemia 
 
 
The effect of a single genetic mutation can vary greatly between different types of cells.  
The mutated gene may not be expressed in one tissue but may cause a devastating loss of 
function in another.  To learn about disease mechanisms and generate novel therapies, genetic 
disorders must be studied in the types of cells where the mutations are most deleterious.  
Recently, scientists have begun manipulating cellular identity to create the cell types most 
affected by various genetic diseases.  This dissertation describes the experience of generating 
reprogramming models for three genetic disorders: Ring 14 syndrome, Pearson syndrome, and 
Fanconi anemia.   
Pearson syndrome is a mitochondrial disorder caused by large deletions in mitochondrial 
DNA (mtDNA).  We generated a Pearson syndrome iPS line and an isogenic line that carried 
only healthy mitochondria.  We investigated the effect of the mutant mtDNA on pluripotent cell 
growth and metabolism, then differentiated both lines into blood cells.  Erythroid progenitors 
carrying the mtDNA mutation showed a clear pathological phenotype associated with the 
disease.   
 iii
Ring chromosome 14 causes developmental delay and severe seizures.  Until the work 
described here, there was no opportunity to study cells from ring 14 patients in any cell type 
other than fibroblasts or peripheral blood.  We generated multiple iPS lines that carried the ring 
chromosome, and were able to identify an isogenic, disease-free control line derived from non-
disjunction.  R14-iPS cells were then differentiated down a neuronal lineage, marking the first 
ever neural cells from a ring 14 patient available for study.   
Many laboratories have found that Fanconi anemia cells reprogram very poorly.  In our 
non-viral reprogramming system, we were surprised to find that Fanconi cells reprogrammed 
nearly as well as cells from their wild-type littermates.  These results provide new insight into 
why published attempts to reprogram FA cells have failed. 
This dissertation contains these three examples of manipulating cellular identity to learn 
about rare genetic diseases.  
 iv
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Chapter 1: Introduction and Background  
 
Introduction 
 
When a sperm fertilizes an egg, the genetic material from both gametes combines to form 
a single nucleus.  This nucleus is located in a giant cell called the zygote.  Over the next few days 
the zygote undergoes many cell divisions and eventually becomes a hollow, spherical structure 
called a blastocyst.  Most of the blastocyst will go on to form the placenta, but about a dozen 
small cells tucked inside the protective outer coating will divide and create first a fetus, then a 
newborn, then an adult human.  These dozen cells are called the inner cell mass.  As 
development progresses, their cellular identities will shift and change, becoming more and more 
specialized.  Genes will be turned on and off, proteins will be generated and degraded, and the 
cells' functions and behaviors will evolve.  Nine months later, those dozen cells will have 
generated an entire human being: fingers and toes, brain and blood.  But sometimes the zygote 
carries a fateful flaw: tiny errors in its DNA sequence can irreversibly alter the course of that 
particular zygote's life.  This dissertation describes the investigation of three such DNA changes, 
and how our growing awareness of cellular identity has led to a deeper understanding of the 
resulting diseases. 
If a scientist removes the inner cell mass from a blastocyst, the cells can be nurtured in a 
laboratory dish.  They can reproduce and eventually will generate millions of embryonic stem 
(ES) cells.  Each ES cell retains the ability to form any tissue of the body, and so is termed 
"pluripotent:" many-potentialed.   
The first derivation of human ES cells, accomplished by James Thomson in 1998, 
captured the imaginations of clinicians and scientists alike (1).  Cellular pluripotency suggested 
 1
revolutionary approaches to learning about and treating human disease.  Researchers began 
developing techniques to coax ES cells to become specialized cell types: heart cells, neurons, 
insulin-producing pancreatic cells, liver cells, and blood cells.  Once these cell types could be 
made, they promised to become revolutionary new tools for learning about and treating human 
diseases.   
But in the United States, research into this promising avenue of investigation flagged as 
opposition sprang up from opponents of embryo research.  New policies severely limited federal 
funding of ES cell studies, impeding US scientists’ ability to work on this versatile new cell type.  
With American research hobbled, scientists from around the globe asserted strong leadership 
positions in the field.  Major stem cell research initiatives grew in the United Kingdom, Israel, 
Singapore, and Japan, fueling the excitement of research communities in these countries (2).  
One flagship center at Kyoto University, the Institute for Frontier Medical Sciences, was 
founded in 1998 with the goal of advancing the field of regenerative medicine by characterizing 
ES cells.  At this institute, Dr. Shinya Yamanaka began tinkering with ES cells and trying to 
understand their hitherto unmatched pluripotency.  Through an ingenious series of experiments, 
Dr. Yamanaka and colleagues developed a new technology to convert fibroblasts and other 
somatic cells into induced pluripotent stem cells (3). 
Dr. Yamanaka’s breakthrough research built upon previous demonstrations that one type 
of cell could be turned into another by expressing transcription factors specific to the target cell; 
for example, expression of the muscle-specific transcription factor MYOD has been known to 
convert fibroblasts into muscle progenitor cells since the 1980s (4).  Dr. Yamanaka and 
Kazutoshi Takahashi, a graduate student in his lab, hypothesized that they could convert 
fibroblasts into pluripotent stem cells by overexpression of embryonic transcription factors.  To 
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observe what they anticipated would be a very rare event, they used cells from a strain of mice 
that carried an antibiotic resistance gene under the control of an embryonic gene promoter (3).  
Cells from this strain of mice would become resistant to antibiotics only if they adopted 
embryonic-like gene expression.  By infecting these cells with retroviruses containing candidate 
genes, Dr. Yamanaka and Dr. Takahashi hoped to discover combinations of transcription factors 
that conferred antibiotic resistance by activating an embryonic gene expression program.  Their 
enormous challenge was to identify a combination of genes that could accomplish such a drastic 
transformation of cellular identity. 
Twenty-four genes involved in pluripotent cell identity were chosen as candidates for 
induction of pluripotency.  No single factor was able to induce antibiotic resistance, but when all 
24 were transfected at the same time, some rare cells successfully activated embryonic 
expression patterns and acquired resistance to the antibiotic.  When the resistant cells were 
grown in culture, about half of them demonstrated characteristics of pluripotent stem cells, 
including morphology, growth rate, and expression of key embryonic genes.  These cells were 
named induced pluripotent stem (iPS) cells. 
After the successful initial reprogramming of fibroblasts into pluripotent stem cells, the 
investigators began to narrow down the field of responsible genes.  They infected cells with 
viruses containing all possible combinations of 23 genes, leaving one gene out each time; those 
experiments that “failed” identified the genes that were required for embryonic gene expression.  
This led to the identification of four genes which were indispensable for efficient 
reprogramming: OCT4, SOX2, KLF4, and MYC (collectively termed OSKM) (3).  These genes 
are now colloquially referred to as the “Yamanaka factors” and comprise the four genes most 
commonly used to induce pluripotency. 
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The initial murine iPS cells were evaluated for pluripotency by multiple assays.  First, 
cell surface markers were investigated, which demonstrated the similarities between iPS and ES 
cells.  Then microarrays comparing gene expression profiles between iPS and ES cells 
demonstrated that although the cell types were distinguishable, they shared virtually all 
characteristic expression patterns.  Next, teratoma assays showed that the iPS cells were capable 
of differentiating into cell types of all three germ layers, a crucial test to prove their pluripotency.  
Finally, the authors established that when iPS cells were injected into blastocysts, they 
contributed to all three germ layers in developing embryos (3).  Since the initial report, murine 
iPS cells’ pluripotency has been further confirmed by the birth of live chimeras, germline 
transmission, and the most stringent test for pluripotency, tetraploid complementation, which 
entails injecting pluripotent cells into engineered tetraploid embryos and obtaining a complete 
mouse derived entirely from the iPS cells (5-8). 
One of the most impressive features of Dr. Yamanaka's discovery was its robust 
repeatability.  Within 18 months of publication of the seminal paper describing mouse 
reprogramming, three independent laboratories reported successful derivation of human iPS 
cells, and shortly thereafter two groups produced iPS cells from patients with a multitude of 
diseases (9-13).  By mid-2008, it was clear that Dr. Yamanaka’s new reprogramming technology 
had revolutionized how scientists thought of cellular identity.  While Drs. Weintraub, Graf, 
Busslinger, and colleagues had investigated rather modest cell identity changes between 
mesodermal or hematopoietic lineages, an engineered cell identity change as dramatic as 
reversion of differentiated cells to pluripotency was not envisioned as plausible before Dr. 
Yamanaka’s work (4, 14, 15).   
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Two main types of pluripotent stem cell now exist: ES cells, derived from the inner cell 
mass of blastocysts, and iPS cells, created by reprogramming adult cells.  ES and iPS cells 
demonstrate highly similar gene expression and epigenetic regulation and in some cases are 
functionally interchangeable (16-19).  However, there are a number of important differences 
between the two cell types.   
First of all, ongoing research into the similarities and differences between iPS and ES 
cells has made it clear that the two cell types are not completely identical (17, 20, 21).  During 
iPS cell generation, reprogramming is often unable to completely eradicate epigenetic markers of 
the original cell type, which is termed epigenetic memory.  These iPS lines retain some 
epigenetic signatures of their tissue of origin and are most effective at differentiating into the 
tissue type from which they were originally derived.  For example, some iPS lines derived from 
blood cells differentiate into a hematopoietic lineage more efficiently than do iPS lines derived 
from skin cells (16, 18).  This suggests that many iPS cell lines have not reached a true 
pluripotent state, and further research into the epigenetics underlying reprogramming must be 
done before iPS cells can be considered as unbiased as ES cells.   
Secondly, iPS cells have vastly greater potential for disease research and eventual 
therapeutics than do ES cells.  Before iPS technology, the only ways to obtain human pluripotent 
stem cells carrying a particular genetic disease was to recruit parents undergoing preimplantation 
genetic diagnosis and generate ES cells from their discarded blastocysts (22, 23).  Now, using a 
reprogramming approach, researchers can generate iPS cells from patients bearing virtually any 
remarkable genotype.  This change is reflected in the large and growing number of disease-
specific human pluripotent stem cell lines that have to date been described (24).  iPS cells also 
have an important clinical advantage over ES cells: the genome of an iPS cell matches the 
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genome of the patient from whom it was derived.  Thus, if organs or tissues can one day be 
derived from iPS cells, they will be less apt to face immune rejection when transplanted than 
tissues derived from allogeneic ES cells (25, 26).  This advantage may be maintained even in 
cases where a patient’s disease is genetic, if genetic correction can be applied to the cells before 
transplant (27). 
Finally, human ES cell isolation requires the destruction of human blastocysts.  This 
concern has led to regulatory, financial, and logistical hurdles for research involving ES cells.  In 
the United States, derivation of ES cells is subject to close regulation by Embryonic Stem Cell 
Research Oversight Committees, and research funding from the federal government is restricted 
to a limited subset of ES cell lines that have passed scrutiny by an ethical review committee of 
the National Institutes of Health (28, 29).  Derivation of iPS cells does not involve human 
embryos, so the use of iPS cells raises fewer ethical questions and is subject to less federal 
oversight (1, 11).  Thus, in addition to the considerable advantages of iPS cells for disease 
research applications, they likewise provide significant practical advantages relative to ES cells. 
Although a few laboratories still focus on ES cells, the many advantages of iPS cells have 
made the latter a much more common research tool.  For scientists interested in genetic, cell-
autonomous disorders, research can be performed on platforms as diverse as epidemiology, 
human genetics, animal modeling, and in vitro cell culture.  Each of these approaches provides 
different kinds of information about the disorder under investigation, and each has its own 
limitations.  The advent of patient-specific stem cells has led to a completely novel platform for 
studying human disease.   
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Design and verification of an iPS cell-based disease model 
 
The premise of iPS cell-based disease modeling is simple: differentiate the iPS cell into 
the cell type affected by the disease and identify a disease-specific phenotype (Figure 1.1).  
Researchers can then learn about disease mechanisms, search for new drug treatments, or prepare 
to perform cellular therapy.  These goals underlie all iPS cell-based disease models, including 
those described in this dissertation, but creation and execution of a successful disease model is 
more complicated than it may first appear.  There are five discrete choices to be made: which 
disease, which control, which target cell type, which differentiation protocol, and which disease-
relevant phenotype to investigate. 
1) Disease choice.  During reprogramming, the cellular epigenome is reset and all 
environmental conditions are normalized, such that the only disease risk factors carried by the 
resulting iPS cells are those encoded in its genome (30, 31).  With this in mind, researchers to 
date have mostly chosen to create their first disease models either from strictly genetic diseases 
(e.g., trisomy 21, Shwachman-Diamond syndrome, dyskeratosis congenita) or from a genetic 
version of a more complex disease (e.g., the SOD1-mutant familial amyotrophic lateral sclerosis, 
the PINK1-mutant familial Parkinson’s disease, the APP-mutant familial Alzheimer’s disease) 
(32-37).  By ensuring that the iPS cells carry the predisposition to disease, researchers hope to be 
able to identify a disease-related phenotype when they differentiate the cells.   
2) Choice of control.  The goal of creating an iPS cell-based disease model is to 
phenotypically distinguish the disease-bearing cells from the control cells.  But results will vary 
drastically depending on which control cells are used.  Unfortunately, different pluripotent cell 
lines are notoriously variable in their differentiation tendencies and abilities.  This is true both  
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Figure 1.1: Modeling genetic diseases using induced pluripotent stem cells.  Patient tissues are 
reprogrammed, then genetically corrected.  The two lines are differentiated into the tissue type affected by the 
disease.  Any difference in phenotype between the two lines is attributable to the gene defect. 
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between iPS lines generated from different individuals and even between iPS lines generated in 
parallel from a single patient (38-40).  For this reason, the best control for any disease model is 
to correct the disease genotype in the patient’s affected iPS line, rendering it genetically wild-
type (WT).  Any phenotypic discordance observed in cells differentiated from these lines can be 
immediately ascribed to the disease genotype.  Depending on the nature of the disease, correction 
may be achieved by viral rescue, genome editing, subcloning, or other manipulations.  If this can 
be accomplished, the disease-carrying and the repaired lines are isogenic, distinguishable only by 
the status of the disease allele or genotype.   
3) Target cell type.  Genetic diseases manifest differently in different cell types.  A 
mutation that creates a toxic protein in one cell type may be harmless in another—for example, 
patients with Fanconi anemia endure bone marrow failure but are neurologically normal, while 
patients with ring 14 syndrome suffer devastating developmental delays but have normal 
hematopoiesis (41, 42).  Once the disease is chosen and a control line has been created, 
researchers must determine which target cell should be used in their model.  This choice is 
influenced by the type of cell most strongly affected in patients, the likelihood of identifying a 
cell-autonomous phenotype, and the availability of protocols to generate target cell types in vitro.  
Scientists must also consider the best method to verify that the cells they generate are equivalent 
to the target cells, such as surface markers, transcriptome or epigenetic analysis, or functional 
assays.  
4) Differentiation protocol.  In many cases, in vitro differentiation protocols are a limiting 
factor for disease modeling.  Even though scientists have worked on directed differentiation 
approaches for decades, this step is usually the highest hurdle in a stem cell-based model.  
Differentiation protocols generally attempt to recapitulate the cellular niche present during 
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embryonic development.  Various protocols provide cytokines, 3D organization, mechanical 
stimuli, exogenous transcription factors, or co-culture with supportive stromal cells in an attempt 
to induce directed cellular identity changes (43-47).  Unfortunately, many cell types derived 
from human iPS cells are not fully differentiated or more closely resemble immature fetal tissue 
than the mature adult organs affected by disease (48-53).  In these cases, other cellular identity 
manipulations may yield better models than approaches beginning with pluripotent cells.  One 
such possibility is transdifferentiation of one somatic cell type to another.  This has been 
particularly successful in the cardiac field, where iPS cell-derived cardiomyocytes remain 
immature but more adult-like cardiomyocytes have been successfully derived from fibroblasts 
(51, 54).  Researchers have been even more successful at generating adult-like cardiomyocytes 
using in vivo cellular identity transformations, but this approach is unlikely to translate into 
cellular disease models (55, 56).  In the case of human definitive hematopoietic stem cells 
(HSCs), a significant part of the reason they have never been successfully derived in vitro is 
likely because researchers lack suitable culture conditions to maintain and expand these 
evanescent cells.  Where appropriate chemical manipulations, ideal starting cell types, or cell 
culture conditions remain poorly defined, directed differentiation protocols represent a critical 
rate-limiting step in disease modeling (57).   
5) Identification of disease-relevant phenotype.  The final step in creating a stem cell-
based disease model is the identification of a disease-specific phenotype in the resulting cells.  In 
order for a disease model to be informative, its primary phenotype should be directly relevant to 
the disease, which is why the best cellular phenotypes are those that are also seen in primary 
patient tissues.  These include phenotypes like arrhythmias in cardiomyocytes with long QT 
syndrome and abnormal glucosylceramide accumulations in macrophages with Gaucher disease 
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(58-60).  The importance of a strong, disease-relevant phenotype is two-fold.  First, the cellular 
phenotype is the basis of the model's utility for research on the disease mechanism.  As the 
model is studied, it will provide information about the mechanism by which the cell produces the 
phenotype.  If the phenotype is unrelated to the actual disease, the model will be of no benefit for 
disease etiology research.  Secondly, a strong cellular phenotype can be the basis for a drug 
screen.  If a phenotype can be measured in a high-throughput assay, the model can become a 
platform for discovery of new therapeutic approaches.   
It may be that in certain diseases, no relevant disease-specific phenotype will be 
forthcoming.  This is especially likely in disorders whose basic mechanisms are not yet 
understood—a cellular phenotype may exist, but scientists have yet to discover what it is.  In 
these cases, the phenotype search itself is likely to yield information critical to understanding the 
disease process.   
 
Applications of iPS cell-based disease models 
 
Once a model exists for a given disease with an appropriate control, an accurate 
differentiation protocol, and a biologically-relevant cellular phenotype, it can be put to work 
understanding disease mechanism, screening for drugs, or eventual cellular therapy (Figure 1.2).  
Each of these three goals is applicable to different disorders, depending on the nature of the 
disease and the current state of research in the field.   
For disorders where etiology is unclear, patient-specific iPS cell models may confirm 
current theories or inspire new hypotheses about the origins and progression of the disease (61).  
The opportunity to investigate disease mechanism and phenotypes in the type of cell affected by  
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the condition—rather than in cell lines or cadaveric samples—is a huge step forward for research 
on genetic conditions affecting brain, heart, retina, and other inaccessible organs from which 
scientists cannot obtain living cell samples.   
For disorders whose etiology is understood well enough to identify a cellular phenotype, 
that readout can be used as the basis for a drug screen.  As mentioned above, if the in vitro 
phenotype shares a mechanism with its in vivo clinical manifestation, a drug that can ameliorate 
the in vitro phenotype may be expected to help a patient.  By this logic, once a disease-specific 
cellular phenotype is identified, iPS technology can provide material for high-throughput drug 
screens to identify novel therapeutic agents.   
Figure 1.2: Three applications of iPS cell research. 
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In addition to identification of new drugs via screens, iPS-derived cells are also expected to 
facilitate the process of drug development.  One of the most common reasons new drug 
candidates fail clinical trials is due to toxicity to patients' liver, heart, or brain (62).  By 
producing human hepatocytes, cardiomyocytes, and neurons in vitro, scientists will be able to 
screen potential drug compounds for toxicity at a much earlier stage of development (63-65).  
Not only is this likely to prevent toxic drugs from reaching clinical trials, but will also give 
researchers a chance to tweak the molecular makeup of their compound in order to minimize 
toxicity before investing millions of dollars in moving the drug to the clinic.   
Most genetic conditions could reap rewards from the in vitro research and drug screens 
described above.  But reprogramming-based cellular transplantation therapy, the most 
complicated and difficult goal for patient-specific stem cell research, is only an option for a 
select subset of diseases.  Disorders caused by an overabundance of cells (e.g. cancer), 
widespread cell dysfunction (e.g. Alzheimer's disease), or cellular disorganization (e.g. autism 
(66)), are not candidates for cellular transplantation therapy.  Only those rare conditions where 
the symptoms are caused by lack of a certain group of cells (e.g. bone marrow failure, type I 
diabetes, Parkinson's disease) could be successfully cured by transplantation of cells from an 
outside source.   
 
History of clinical stem cell therapy 
 
One stem cell-based therapy is already widely accepted and utilized worldwide: 
hematopoietic stem cell transplantation.  This practice was pioneered by Dr.  E.  Donnall Thomas 
in 1959, when he demonstrated that the bone marrow from one identical twin could reconstitute 
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the blood system of the other twin, who suffered from leukemia (67).  Initial treatment success 
was limited to those rare patients who had identical twins, because transplantation of bone 
marrow from nonidentical donors resulted in severe, systemic attack of the new immune system 
against the recipient’s organs, a condition termed graft-versus-host disease.  After ten years of 
exhaustive research into human leukocyte antigen (HLA) matching and immunosuppression, Dr.  
Thomas’s team successfully performed a bone marrow transplant from one non-twin sibling to 
another (68, 69).  This extraordinary feat earned Dr.  Thomas a Nobel Prize in 1990 for his 
contributions to cellular transplantation. 
Since 1959, the practice of hematopoietic stem cell transplantation has become 
widespread.  Advanced and inexpensive HLA typing has allowed the collection of millions of 
potential bone marrow donors in national registries, and an increased understanding of 
hematology and immunology has lessened the risks associated with transplant.  However, even 
with high-quality HLA matches, bone marrow transplant still carries a treatment-related 
mortality of 5-20% in the first few months (70, 71).  The dangers of this period include extreme 
neutropenia and consequent infections, failure of the transplant to engraft, and acute and chronic 
graft-versus-host disease.  Various features of the transplant determine the likelihood of these 
complications, including the number of hematopoietic stem cells that are transplanted and the 
degree of mismatches at both major and minor histocompatability loci.  Most patients who 
survive the transplant itself have a good long-term prognosis, with overall five-year survival 
rates around 70-80% for non-cancer patients (72-75).   
Hematopoietic stem cells' robust differentiation potential allows a few hundred milliliters 
of donor marrow to reconstitute an entire organ in the recipient.  Following intravenous infusion, 
the transplanted hematopoietic stem cells home in on the bone marrow and engraft into the 
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niches already present there.  No cellular organization is required for transplant to occur, making 
the blood system an attractive starting place for working toward iPS cell-derived cellular therapy.  
Combined with bone marrow transplant's long history and established clinical efficacy, this 
advantage makes the hematopoietic stem cell arguably more feasible for clinical application than 
stem cells from organ systems; however, the quest to convert human pluripotent stem cells into 
functional, engraftable hematopoietic stem cells has been challenging and has not yet proven 
successful.  This complex task requires a thorough understanding of the developmental events 
that lead to formation of HSCs in vivo and approaches to mimic these events in the laboratory. 
 
In vitro differentiation of pluripotent cells into blood  
 
Hematopoietic development is strikingly similar in mice and humans, so researchers have 
turned to the mouse to learn about mammalian blood development.  It is hoped that an 
exhaustive understanding of the signaling, migration, and molecular events in the developing 
mouse hematopoietic system will inform our ability to direct similar development in vitro from 
human pluripotent stem cells. 
In both mouse and human, the first hematopoietic cells are found in the extraembryonic 
yolk sac.  These are referred to as primitive hematopoietic progenitors because the blood cells 
they produce have more embryonic characteristics than those that arise later in development.  
This is especially true of early red blood cells, which express embryonic forms of hemoglobin 
with greater affinity for oxygen, as is appropriate for the hypoxic fetal environment.  Around day 
10.5 of mouse development, the first HSCs arise in the aorta-gonad-mesonephros region of the 
developing mouse embryo (76, 77).  Hemogenic endothelium forms on the ventral wall of the 
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aorta, squeezing the first true HSCs into the growing circulatory system (78-80).  These 
definitive HSCs, possibly along with some primitive progenitors from the yolk sac, colonize the 
fetal liver (81).  The main hematopoietic function of the liver appears to be to provide a 
permissive environment for the HSCs to grow and expand, as their numbers increase greatly at 
this stage of development (82).  Finally, HSCs colonize the bone marrow, where they will be 
responsible for maintaining the immune and blood systems for the rest of the animal’s life (83). 
Two in vitro culture systems are currently employed to coax mammalian pluripotent stem 
cells down the path of hematopoietic differentiation: two-dimensional culture on supportive OP9 
stromal cells, and aggregation of differentiating cells into three-dimensional balls of cells called 
embryoid bodies (EBs) (84, 85).  In both systems, exogenous cytokines are applied at defined 
intervals and concentrations to mimic the evolution of cellular identity that occurs during 
development.  If these mouse cells are infected with viruses expressing homeodomain-containing 
transcriptional regulators like CDX4 and/or HOXB4, the systems create cells that fulfill the 
definition of HSCs: long-term, multilineage engraftment (86-88).  However, the activity of these 
exogenous factors does not appear to be as effective in human lines as it is in the mouse 
background (87, 89).  Both EB creation and co-culture with stromal cells lead human pluripotent 
stem cells to differentiate into the hematopoietic lineage, as measured by robust expression of 
CD34, CD45, and other hematopoietic markers (87, 90).  In spite of this, when these cells are 
transplanted into immunodeficient mice, they fail to generate high-level, multilineage, long-term 
engraftment (87).  The reasons for the observed differences between mouse and human 
pluripotent-to-hematopoietic stem cell differentiation are active areas of inquiry.  Achieving 
stable multilineage engraftment of human HSCs derived from pluripotent stem cells remains a 
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major goal in hematology research, and must be achieved before patient-specific iPS cells can be 
used for cellular therapy for bone marrow failure. 
 
Summary of work described in this dissertation 
 
This dissertation focuses on three genetic diseases: Pearson syndrome, ring 14 syndrome, 
and Fanconi anemia.  We manipulated cellular identity to learn more about each of these 
diseases, by creating iPS cells from patients with Pearson syndrome and ring 14 syndrome, and 
by studying the reprogramming process in Fanconi anemia cells.   
Chapter 2: Pearson syndrome.  The presence of a mitochondrial deletion is the well-
documented cause of Pearson syndrome, but its effect on pluripotent cellular metabolism and 
hematopoietic differentiation has never before been studied.  Here, we describe creation of 
Pearson syndrome iPS cells and an isogenic line completely free of disease.  We employed these 
tools to investigate the specific metabolic defects of PS-iPS cells and create in vitro-derived 
Pearson syndrome blood cells.  In the erythroid population resulting from this differentiation, we 
found pathognomonic iron-positive staining specifically in cells carrying the mtDNA deletion.   
Chapter 3: Ring 14 syndrome.  The single most important question in the field of ring 14 
syndrome research is how the presence of the ring chromosome during brain development leads 
to a seizure disorder.  Investigation of this question has been stymied by the complete 
inaccessibility of relevant cells.  Until the work described here, there was no opportunity to study 
the ring chromosome in any cell type other than fibroblasts or peripheral blood.  We report the 
creation of iPS cells carrying a ring chromosome 14, and observe dynamic changes in the 
chromosome 14 karyotype over time.  Following a non-disjunction event, we identified a 
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subclone that carried two linear, uniparental disomic copies of chromosome 14.  R14-iPS were 
then differentiated down a neuronal lineage, marking the first neural cells from a ring 14 patient 
available for study.  This project is ongoing, and we are currently comparing differentiation 
efficiency and neural phenotypes between isogenic iPS lines carrying the ring and carrying 
disomic chromosome 14.   
Chapter 4: Fanconi anemia.  Around the world, dozens of attempts have been made to 
reprogram cells from patients with Fanconi anemia, yet only one of them has succeeded.  We set 
out to investigate this FA reprogramming defect in a secondary murine system, and were 
surprised to find that the FA cells reprogrammed nearly as well as cells from their WT 
littermates.  These results provide new insight into why published attempts to reprogram FA 
cells have failed, although an elegant understanding of the problem is still evasive. 
Together, these chapters describe three examples of manipulating cellular identity to 
learn about rare genetic diseases.   
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Chapter 2: Pearson Syndrome 
 
Introduction 
 
Mitochondrial DNA (mtDNA) mutations are implicated in numerous human disorders 
ranging from rare multisystem congenital diseases to common acquired degenerative disorders 
such as Parkinson's disease (88, 91-95).  No curative therapies exist for mitochondrial disease, 
and consequently mtDNA mutations cause significant morbidity and mortality (96).   
In congenital mtDNA disorders, a mixture of normal and mutant mtDNA, termed 
heteroplasmy, is inherited from the oocyte at fertilization and partitioned differentially in tissues 
during embryogenesis (88, 97).  The degree and distribution of heteroplasmy in adult tissues 
determines the severity and marked phenotypic heterogeneity of the disease.  Pearson marrow 
pancreas syndrome, also called Pearson syndrome (PS), is a congenital multisystem disorder 
caused by large deletions in the mitochondrial genome and is characterized by life-threatening 
bone marrow failure and metabolic derangements (98, 99).  The cause of the hematopoietic 
failure in PS is unknown, and experimental models to reproduce tissue-specific defects in PS and 
other mtDNA disorders are needed.   
 
Cybrids, the mitochondrial mutation research tool 
Because mtDNA sequences are difficult to manipulate in cells, cybrid (cytoplasmic 
hybrid) cell lines have been the most common model for studying mitochondrial disorders (100, 
101).  Cybrids are created by fusion of cytoplasts harboring mutant mtDNA with a cell depleted 
of mitochondria, called 0 (rho-naught) cells.  The resulting cybrid contains the nucleus of the 
 19
0 cancer cell line and the mutant mitochondria of interest.  Cybrids have provided insights into 
the role of mtDNA in cancer, the effects of specific mtDNA mutations, and inter-species 
mitochondrial complementarity (95, 101).  However, the cybrid approach is heavily dependent 
upon the cell type chosen to receive the affected mitochondria.  When different 0 cell lines are 
used as the nuclear donor, experimental results vary dramatically (102, 103).  This is widely 
recognized as the most severe limitation of cellular research into mitochondrial disorders. 
Pearson syndrome mutations have been studied only using cybrids created from 0 
cancer cell lines (104, 105).  Because cell type-specific mitochondrial function is crucially 
relevant to disease processes, an experimental system in which the effects of mtDNA mutations 
could be studied in specific human cell types would be of great value.  We have created such a 
system for blood, and it is proof-of-principle for similar applications in other organs.   
 
Reprogramming cells that carry deleted mtDNA 
Somatic cells can be directly reprogrammed using defined genetic factors to yield iPS 
cells, which have the capacity to differentiate into any tissue (11-13, 106).  Direct 
reprogramming allows the creation of patient-specific pluripotent cells that retain the 
cytoplasmic contents of donor cells, including disease-associated mtDNA.  We sought to 
generate iPS cells carrying mutant mtDNA in order to investigate tissue-specific effects of 
mitochondrial dysfunction.  We describe the derivation of iPS cells bearing a pathogenic mtDNA 
deletion from a patient with PS.  We observed changes in heteroplasmy during culture of PS-iPS 
cells, which allowed us to isolate isogenic iPS cells with undetectable levels of mutant mtDNA.  
Comparison of PS-iPS cells with varying degrees of heteroplasmy in vitro revealed defects in 
growth and mitochondrial function, and directed differentiation into the hematopoietic lineage 
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revealed a tissue-specific phenotype characteristic of PS.  Our results demonstrate that 
reprogramming of somatic cells from patients with Pearson syndrome can yield patient-identical 
pluripotent stem cells varying in mtDNA heteroplasmy, providing unique tools to study tissue-
specific effects of mtDNA mutations. 
 
Materials and Methods 
 
Patient material 
Biological samples were procured under protocols approved by the Institutional Review 
Board at Boston Children’s Hospital.  Standard histological evaluations were performed by the 
Department of Pathology, Boston Children’s Hospital.   
  
DNA isolation 
Genomic DNA was isolated from peripheral blood or bone marrow using the QIAamp 
DNA Blood Maxi Kit or the DNeasy Blood and Tissue Kit (Qiagen).  DNA was isolated from 
fibroblast and iPS cell lines by SDS/Proteinase K lysis followed by phenol/chloroform extraction 
and ethanol precipitation. 
 
Cell lines and culture  
Pearson syndrome patient bone marrow-derived fibroblasts (PS-Fib) were isolated by 
plating 150 uL of liquid bone marrow in DMEM/15% FCS.  Media was changed every three 
days until outgrowths appeared (approximately two weeks), and thereafter cells were expanded 
by routine trypsinization and subculture.  Cells were characterized for mutant mtDNA at passage 
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two.  Pearson syndrome fibroblasts (GM04516) and lymphocytes (GM04515) and Kearns-Sayre 
syndrome fibroblasts (GM06225) and lymphocytes (GM06224) were obtained from the Coriell 
Institute for Medical Research.   
 
Long range PCR 
Long range PCR to detect mitochondrial DNA deletions was performed by amplifying 
100-500 ng of template DNA using the Expand Long Template PCR system (Roche Diagnostics) 
according to manufacturer’s instructions.  The deletion locations were mapped using PCR, 
restriction digests, and Sanger sequencing.  Nucleotide positions were assigned per the revised 
Cambridge Reference Sequence of human mitochondrial DNA.  Sequence analysis was 
performed using data from www.mitomap.org. 
 
Mitochondrial DNA FISH 
Templates for probes were amplified by PCR.  COMMON probe was labeled with 
digoxigenin using the DIG-Nick Translation Mix (Roche) and CHBMDF1 FISH probe was 
labeled using the Biotin-Nick Translation Mix (Roche).  Fibroblasts were prepared on coverslips 
as previously described (107, 108).  COMMON and CHBMDF1 probes were simultaneously 
hybridized on the coverslips in 50% formamide, 2X SSC by heating to 85° C for 2.5 minutes 
followed by incubation at room temperature overnight.  Coverslips were washed in TBS 0.05% 
Tween (TBST) and incubated in TBST with 0.05% W/V Blocking Reagent (Roche) with FITC 
conjugated anti-Dig and Alexa Fluor 594 conjugated streptavidin at room temperature for one 
hour.  Coverslips were washed in TBST, dehydrated and mounted in Prolong Gold (Invitrogen), 
and analyzed by epifluorescence microscopy. 
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Heteroplasmy determination by quantitative real-time PCR 
Quantitative real-time PCR measurements were performed using 30 ng of template DNA 
and Brilliant SYBR Green QPCR Master Mix (Stratagene) with primers CHBMDF1F and 
CHBMDF1R for the mutant mtDNA species and WTmitoF and WTmitoR for all mtDNA 
molecules.  Primer pairs were verified for linear amplification over a 100-fold range of input 
DNA.   
 
Single-cell multiplex real-time PCR 
Primer pairs and probe sets were optimized and validated for sensitivity and specificity.  
Fibroblasts were collected by trypsinization and single cells were FACS sorted into individual 
wells of a 96-well qPCR plate containing 10 uL of 10% SideStep Lysis buffer.  Amplification 
was performed with appropriate negative and positive controls using primers/probes at the 
concentrations described above with Brilliant II QPCR Master Mix in a Stratagene MX3000P 
QPCR system, and results were graphed and scored as described in the figure legends. 
 
Mitochondrial complex quantity and activity assays 
Quantification of complex I, complex IV, frataxin and PDH was performed using the 
MetaPath MitoDisease 4-Plex Dipstick Array (MitoSciences, Abcam) according to 
manufacturer’s instructions.  Complex I, III and IV activity were respectively determined using 
the Complex I Enzyme Activity Dipstick Assay Kit, Cyt C Reductase Human Profiling ELISA 
Kit, and Complex IV Enzyme Activity Dipstick Assay Kit (MitoSciences, Abcam) (46).  A 
standard curve was established for each assay using a range of normal fibroblast protein 
concentrations.  0.5 and 5 ug of protein extract were used for each sample in duplicate for 
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MetaPath quantity assays.  1 and 10 ug of protein extract were used for each sample in duplicate 
for complex I and IV activity assays.  Quantification was performed by scanning the dipsticks 
followed by image analysis using Adobe Photoshop as described in the manufacturer’s 
instructions.  34 ug protein extract was used in triplicate for the complex III activity assay, and 
quantification was performed using a microplate reader.  Results are shown as normalized to 
quantity or activity of complexes in WT cells. 
 
Direct reprogramming and iPS cell characterization 
Derivation, culture, characterization and differentiation of iPS cells was as described 
(109) with modifications to protocol as noted in the text.  iPS lines were cultured on irradiated 
MEF feeder cells or hESC-qualified Matrigel (BD Biosciences).  PS-iPS cells were generally 
passaged every 6-7 days, with manual removal of differentiated cells under a dissecting 
microscope, release of colonies with Collagenase IV (Invitrogen) or Dispase (Stem Cell 
Technologies), and fragmentation and collection using a cell scraper.  Teratomas were formed as 
described (109) by intramuscular injection of iPS cells in immunodeficient mice under approved 
animal use protocols.  Histology was performed at the Dana-Farber Harvard Cancer Center 
Rodent Histopathology core facility.   
 
Immunostaining of iPS cells 
iPS lines were grown on glass coverslips and stained with: (1) OCT4 rabbit polyclonal 
antibody (1:300; Abcam) with Alexa-Fluor 488 chicken-anti-rabbit secondary antibody (1:1000; 
Life Technologies); (2) SSEA4 mouse monoclonal antibody pre-conjugated to Alexa Fluor 647 
(1:100; BD Biosciences); (3) NANOG rabbit polyclonal antibody (1:200; Abcam) with Alexa-
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Fluor 488 chicken-anti-rabbit secondary antibody; (4) TRA-1-60 mouse monoclonal antibody 
(1:100; Millipore) with Alexa-Fluor 594 goat-anti-mouse secondary antibody (1:1000; Life 
Technologies); (5) TRA-1-81 mouse monoclonal antibody (1:100; Millipore) with Alexa-Fluor 
594 goat-anti-mouse secondary antibody.   
  
Reverse-transcription PCR  
RNA was made using Trizol, and cDNA was made with Superscript III (Invitrogen), 
according to manufacturer’s protocols.  PCR was performed using gene-specific primers using 
SYBR green SsoAdvanced polymerase (Bio-rad).   
 
Southern blots 
10 ug of genomic DNA was digested with NcoI, separated on a 0.6% agarose gel and 
transferred to a positively charged nylon membrane.  For evaluation of heteroplasmy, 
hybridization was performed using a probe corresponding to nucleotide 14840-15261 
(cytochrome b) of the mitochondrial genome, which detects a 7.5 kb band from the intact 
mitochondrial genome and a 5 kb band from the deleted mitochondrial genome in the PS patient.  
Hybridization was performed with Rapid-Hyb buffer (GE Healthcare) according to 
manufacturer’s instructions.  Each reprogramming retrovirus contains an IRES-GFP cassette and 
a single NcoI restriction site, which was used for proviral integration pattern analysis.  The 
proviral integration patterns were determined by cutting with NcoI and probing Southern blots 
with a GFP probe.   
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Live-cell imaging 
iPS cells were plated as single cells on Matrigel (BD Biosciences) in mTESR medium 
(Stem Cell Technologies) in a glass bottom dish (MatTek) on a microscope outfitted with a 
thermo/CO2-regulated chamber and a computer-controlled motorized stage.  Images of iPS 
colonies were obtained at 6-hour intervals in a tiled array and stitched to form a single composite 
image.  The surface area of the colony was measured using Elements AR (Nikon) software.  
Growth analysis ended at 6 days or when the colony grew into an adjacent colony or when the 
colony outgrew nine low-power fields. 
 
Mitochondrial membrane potential 
iPS cells were incubated in hES cell medium containing 7 nM tetramethylrhodamine, 
ethyl ester (TMRE) (Invitrogen) and 100 nM MitoTracker Green (MTG) (Invitrogen) for 90 
minutes.  Immediately prior to imaging, this medium was replaced with phenol red-free hES cell 
growth medium containing 100 nM TMRE.  Live cells were imaged by epifluorescence 
microscopy.   
 
Extracellular flux analysis 
Extracellular flux analysis was performed using the Seahorse platform as previously 
described (110).  PS-iPS cells cultured on Matrigel were trypsinized to single cells and plated 
onto Seahorse 24-well analysis plates at a density of 50,000 single cells per well in mTESR 
media containing 10 uM compound Y-27632 (Sigma).  Each cell line was assayed in 
quadruplicate.  One day later, the cells were analyzed for OXPHOS function (Injection 1: 20 uM 
oligomycin; Injection 2: 3 uM CCCP; Injection 3: 10 uM antimycin and 10 uM rotenone) and 
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glycolysis function (Injection 1: 250 mM glucose; Injection 2: 20 uM oligomycin; Injection 3: 
1.5 M 2-DG).  The listed injection concentrations are 10x the final concentration.  Results were 
normalized for protein concentration in each well and analyzed by Seahorse XF24 software.   
To quantify extracellular flux analyses, background signals were removed by subtracting 
final OCR or ECAR values from signals.  Standard deviations were calculated by analytically 
combining averaged data points and their errors from each well into a composite distribution, 
and then summing the variances of the estimated signal and background distributions.  Figure 2.8 
C and E were normalized to PS-iPS1 to account for expected inter-experiment variability in raw 
data.  Significant differences in basal respiration rates were identified by t-test of the normalized 
data (n = 12) averaged over three replicates.  Percentage of oxygen used for ATP production and 
glycolysis activity and the appropriate standard deviations were calculated using Taylor series 
approximations of the mean and variance of the ratio of random variables.   
 
Hematopoietic colony forming assay and sideroblast quantification 
iPS cells were collected as large aggregates and resuspended in EB differentiation 
medium (80% DMEM, 20% FCS (Stem Cell Technologies 06900), 50 ug/ml ascorbic acid, 0.2 
ug/ml holo-transferrin) on low attachment dishes.  After one day, cytokines were added: hSCF 
(300 ng/ml), hFlt3L (300 ng/ml), IL-3 (10 ng/ml), IL-6 (10 ng/ml), G-CSF (50 ng/ml), BMP4 
(50 ng/ml).  Media containing cytokines was replaced every three days for 14-16 days, as 
described (111).  EBs were dissociated and an equal number of cells was plated in MethoCult GF 
H4434 complete methylcellulose medium (Stem Cell Technologies).  After 14-16 days of 
hematopoietic differentiation, CFU colonies were counted by an experienced observer who was 
blind to the identity of the samples.  For sideroblast quantification, CFU-GEMM and BFU-E 
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picked from methylcellulose were washed in PBS, plated on glass slides by Cytospin, and 
stained using Prussian blue.  Erythroid cells without and with iron deposits were scored by a 
hematopathologist who was blind to the sample identity. 
 
Studies and Results 
 
Induced pluripotent stem cells from a patient with Pearson syndrome  
A three year-old patient presented at Boston Children's Hospital with transfusion-
dependent anemia from birth, metabolic acidosis, pancreatic exocrine insufficiency, insulin 
dependent diabetes mellitus, hypothyroidism, and transfusion-related iron overload.  
Examination of the patient’s bone marrow showed vacuolated hematopoietic precursors and 
ringed sideroblasts, which are erythroid progenitors containing inappropriate iron granules in 
their mitochondria (Figure 2.1 A).  Together with her clinical presentation, these findings 
suggested the diagnosis of Pearson syndrome.  We confirmed this diagnosis by identifying a 
2501 base pair deletion in a subset of the patient’s mtDNA from peripheral blood and bone 
marrow (Figure 2.1 B and C).  The deletion from base pairs 10949-13449 interrupts the 
mitochondrial oxidative phosphorylation (OXPHOS) complex I NADH dehydrogenase genes 
ND4 and ND5, and also deletes three tRNAs (LCUN, SAGY, and H) that are necessary for 
translation of all products of the mitochondrial genome (including required components of 
OXPHOS complexes I, III, IV, and V).  We derived a primary fibroblast culture from the 
patient's bone marrow (PS-Fib, Figure 2.1 D), which carried mutant mtDNA in a proportion 
similar to that found in the patient's blood and bone marrow (60-80% of all mitochondrial 
genomes).  By mtDNA FISH and single-cell multiplex PCR analyses, we determined that over 
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95% of cells in the fibroblast population harbored the mutated DNA species (Figure 2.2 A-C).  
As expected, we found quantitative and functional defects in OXPHOS complexes I, III, and IV 
in PS-Fib fibroblasts compared to wild-type (WT) fibroblasts (Figure 2.2 D, E).  These results 
describe patient-specific somatic cells carrying the characteristic genetic and functional defects 
of a mtDNA deletion disorder. 
The PS-Fib line was infected with retroviruses encoding OCT4, SOX2, KLF4, and MYC.  
No pluripotent colonies had emerged after the typical 3-4 weeks of culture under human ES cell 
conditions.  However, continued culture for 8-12 weeks yielded 1-3 colonies, which displayed 
the morphological and functional characteristics of pluripotent stem cells (Figure 2.3).  The same 
Figure 2.1: Diagnosis of a patient with Pearson syndrome.  (A): A vacuolated hematopoietic precursor (left, 
hematoxylin and eosin stain) and ringed sideroblast (right, Prussian blue stain) from the patient’s bone marrow 
aspirate.  (B): Mitochondrial genome long range PCR revealing the patient’s large mitochondrial deletion.  (C): 
Sequence surrounding the breakpoint and its position in the genome.  (D): PS-Fib, the patient bone marrow-
derived fibroblast line that was reprogrammed to create the PS-iPS cells (40x). 
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Figure 2.2: Characterization of PS fibroblasts.  (A): Location of the patient’s 2.5 kb mutation in the 
mitochondrial genome and fluorescence in situ hybridization comparing WT and patient fibroblasts.  The red 
probe covers a stretch of the mtDNA lost in the patient while the green probe covers an unaffected region.  (B): 
Heteroplasmy of patient peripheral blood, bone marrow, and bone marrow-derived fibroblasts as measured by 
qPCR.  (C): Multiplex qPCR performed at the single cell level on the patient’s bone marrow derived fibroblasts.  
(D): Quantification of electron transport chain protein complexes by sandwich ELISA.  Quantity is normalized 
to frataxin.  (E): Activity of electron transport chain complexes.  Complex I activity is measured by a 
nitrotetrazolium blue-based assay, complex III and complex IV activity are measured by cytochrome c assays 
coupled to horseradish peroxidase and diamino benzidinetetrachloride staining.  All error bars indicate standard 
deviation. 
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low efficiency and delayed kinetics of iPS cell derivation were observed in three independent 
reprogramming experiments from this patient's cells.  We focused our analyses on three Pearson 
syndrome iPS clones (PS-iPS, clones 1-3), each derived from an independent reprogramming 
experiment.   
Figure 2.3: Generation of PS-iPS cells.  (A): Brightfield images of Pearson syndrome iPS (PS-iPS) cell lines 1, 
2, and 3 grown on Matrigel (40x).  (B): Immunofluorescence staining for human pluripotency markers (100x).  
(C): RT-PCR of pluripotency associated genes demonstrates expression in PS-iPS lines but not in the patient’s 
bone marrow derived fibroblasts.  (D): Mitochondrial PCR of PS-iPS lines using primers specific for the 
patient’s mutation (upper) or primers that amplify an unaffected region of the mitochondrial genome (lower). 
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 PS-iPS clones demonstrated ES-like cell morphology and self-renewal under ES cell 
culture conditions (Figure 2.3 A).  They expressed high levels of genes associated with 
pluripotency, as measured by immunofluorescence and RT-PCR (Figure 2.3 B and C).  All iPS 
clones carried the pathological mtDNA deletion found in the parent fibroblasts as demonstrated 
by PCR using primers flanking the deletion junction (Figure 2.3 D).  Each line was capable of in 
vitro differentiation into embryoid bodies and, when injected into immunodeficient mice, 
showed the capacity to yield teratomas that included tissues from all three embryonic germ 
layers and differentiate into embryoid bodies during in vitro culture (Figure 2.4).  These data 
demonstrate the derivation of human iPS cell lines from a patient with Pearson syndrome. 
 
mtDNA heteroplasmy in PS-iPS varies as a function of passage 
In early passage PS-iPS cells, initial burdens of deleted mtDNA varied between 55-70% 
Figure 2.4: PS-iPS differentiation.  All three PS-iPS lines formed teratomas in vivo containing all three germ 
layers.  In addition, each line could be induced to differentiate into embyroid bodies in vitro.   
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when assessed by Southern blot and qPCR (Figure 2.5).  As expected, the PS-iPS cells could be 
continually propagated well beyond the point of senescence compared to the original fibroblast 
population.  When we analyzed the degree of heteroplasmy during culture, we found that the 
clones behaved differently from each other: heteroplasmy in PS-iPS3 remained unchanged at 
approximately 50%, but PS-iPS1 and PS-iPS2 purged mutant mtDNA over time.  Upon 
continued culture of PS-iPS1, we obtained iPS cells with undetectable levels of the mutant 
mtDNA genome (Figure 2.5 B and C).  Importantly, proviral integration analysis performed on 
each PS-iPS line showed a unique pattern that was maintained across passages, demonstrating 
that each line was clonally descended from a single fully reprogrammed PS-Fib cell (Figure 2.6).  
In the case of PS-iPS1, this analysis also demonstrates that the late passage, disease-free cells 
arose by loss of the mutant mtDNA species from the earlier highly-heteroplasmic clone.  These 
data demonstrate clonal variation in changes in mtDNA heteroplasmy during culture, and 
derivation of mutation-free iPS cells from a patient with a mtDNA deletion disorder.   
 
Functional characterization of PS-iPS cells 
With isogenic, pluripotent cell lines that varied only in their degree of mtDNA 
heteroplasmy, we attempted to ascertain the effects of mitochondrial function on pluripotent cell 
growth and differentiation in vitro.  When we used time-lapse imaging to compare colony 
growth between isogenic iPS lines with and without mutant mtDNA, we found that early passage 
PS-iPS1 cells containing 30% deleted mtDNA grew significantly more slowly than isogenic late 
passage PS-iPS1 cells which were purged of deleted genomes (Figure 2.7 A-C).  These 
differences in growth were not attributable to different rates of spontaneous differentiation, as 
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 Figure 2.5, on following page: Characterization of PS-iPS cell heteroplasmy.  (A): Changes in heteroplasmy 
over passage number as measured by Southern blot (quantification of blots in this figure).  (B): Changes in 
heteroplasmy over passage number as measured by qPCR.  (C) Southern blots of PS-iPS1.  Upper blots are probed 
for wild-type and mutant mtDNA.  Lower blots show a retroviral integration pattern created by viruses encoding 
reprogramming factors.  Black lines indicate individual blots.  Left panel shows a single blot probed for wild-type 
and mutant mtDNA (upper) and virus integrations (lower).  Right panel shows two independent blots probed for 
wild-type and mutant mtDNA (upper) and virus integrations (lower).  (D): Southern blot of PS-iPS2 probed for 
wild-type and mutant mitochondrial DNA.  (E): Southern blot of PS-iPS3 probed for wild-type and mutant 
mitochondrial DNA.  
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Figure 2.5: Characterization of PS-iPS cell heteroplasmy (Continued) 
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judged by our observation of cellular and colony morphology during the experiment.  We also 
found that iPS cells that did not carry mutant mtDNA maintained a higher mitochondrial 
membrane potential than isogenic culture of iPS cells carrying 30% mutant mtDNA (Figure 2.7 
D and E).  These results show the restoration of mitochondrial function and growth after 
elimination of mutant mtDNA in cultured PS-iPS cells. 
To investigate the physiological basis of the growth defect in the cells, we analyzed 
mitochondrial respiration and glycolytic function by measuring oxygen consumption and media 
acidification rates (Figure 2.8).  iPS cells carrying about 60% mutant mtDNA (PS-iPS3) showed 
a 50% lower baseline oxidative respiration rate compared to iPS cells carrying low or no mutant 
mtDNA (Figure 2.8 A and C).  This significant oxygen consumption defect could be caused by 
either impaired electron transport chain (ETC) function or by an uncoupling of ETC from ATP 
synthase activity.  To distinguish between these possibilities, we added oligomycin to inhibit 
ATP synthase (Injection 1, OM).  Upon oligomycin addition, all three lines reduced their oxygen 
consumption by similar degrees (64-76%, no significant difference, Figure 2.8 A and D), 
indicating that ATP synthesis efficiency is equivalent between lines.  These results suggest that 
the decreased oxygen consumption found in iPS cells with a high burden of mutant mtDNA 
likely results from impaired ETC function. 
 We next measured glycolytic rates in PS-iPS cells with varying levels of mutant 
mtDNA.  Glycolysis activity was assessed by measuring the extracellular acidification rate 
(ECAR) which varies depending on the cells' production of lactate, a metabolic byproduct of 
glycolysis.  To measure glycolysis levels, cells were starved, then glucose was added to the 
media (Figure 2.8 B, Injection 1 Glu).  PS-iPS3 showed a trend toward higher glycolytic activity  
compared to iPS cells with negligible or low burdens of mutant mtDNA (PS-iPS1 and PS-iPS2), 
 36
but the differences did not achieve statistical significance in aggregate analysis of replicates 
(Figure 2.8 E).  Taken together, the extracellular flux analyses suggest that pluripotent stem cells 
carrying heavy burdens of deleted mtDNA are defective in oxygen consumption due to reduced 
ETC function, which may be partly compensated for by an increase in glycolytic activity. 
Figure 2.7: PS-iPS cell deficits.  (A): PS-iPS1 growth in culture with and without mutant mtDNA, measured 
simultaneously by live cell imaging.  Fold size increase is relative to size at day 0.  (B): Example image of 0% 
heteroplasmy colony from live cell imaging.  (C) Example image of 30% heteroplasmy colony from live cell 
imaging.  D & E:  Mitochondrial membrane staining with MitoTracker Green (stains all mitochondrial 
membranes) and TMRE (stains high membrane potential).  (D) PS-iPS1 with 0% heteroplasmy (40x).  (E) PS-
iPS1 with 30% heteroplasmy (40x).  Insets in both panels are 100x. 
 37
Figure 2.8: Metabolism of PS-iPS cells.  (A): Representative data from extracellular flux analysis of oxygen 
consumption.  Solid black lines indicate time of chemical injections: the ATP synthase poison oligomycin (OM), 
mitochondria uncoupler FCCP, and mitochondrial poisons antimycin and rotenone (A&M).  (B): Representative 
data from extracellular flux analysis of glycolytic function.  Cells begin in relative starvation before the first 
injection of glucose (Glu).  The second injection is oligomycin (OM), followed by the glycolysis inhibitor 2-
Deoxy-D-glucose (2-DG).  (C): Quantification of basal oxygen consumption (respiration) compared to PS-iPS1, 
*** indicates p < 0.0001, n=3.  (D): Quantification of the percentage of oxygen which is used to drive ATP 
synthase, n=3.  (E): Quantification of glycolysis activity, compared to PS-iPS1, n=2.  All error bars indicate 
standard deviation.   
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Hematopoietic differentiation of PS-iPS cells 
Given the hematologic deficits in Pearson syndrome patients, we next assessed the 
capacity of PS-iPS cells to form hematopoietic progenitors in vitro.  We generated EBs from PS-
iPS cells in the presence of mesoderm- and hematopoiesis-inducing factors, followed by 
dissociation and suspension in methylcellulose containing hematopoietic factors.  We found that 
all PS-iPS lines were capable of forming progenitor colonies with typical myeloid, erythroid and 
mixed myeloid-erythroid morphology, verified at the single cell level by Wright-Giemsa staining 
(Figure 2.9 A).  We were unable to detect statistically significant differences among PS-iPS lines 
carrying varying degrees of mutant mtDNA, possibly due to high intrinsic variability in ES-
derived hematopoietic colony forming assays, but we noted a trend towards reduced numbers of 
colonies in samples carrying deleted mtDNA (Figure 2.9 B, n = 4 differentiation experiments).   
Figure 2.9: Hematopoietic differentiation of PS-iPS cells.  (A): Images of hematopoietic colonies derived 
from each PS-iPS line (25-63x).  (B) Quantification of hematopoietic colony forming efficiencies, n=4.  (E = 
BFU-erythroid; GEMM = granulocyte, erythroid, macrophage, megakaryocyte; GM = granulocyte, macrophage; 
M = macrophage) 
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Figure 2.10: Sideroblastic erythroid progenitors.  (A): Erythroid progenitors derived from PS-iPS cells, 
stained for iron with Prussian blue.  The arrow indicates an example iron granule (1000x).  (B): Blinded 
quantification of sideroblasts, scored as percent of erythroid progenitors containing visible iron granules on 
Prussian blue stain.   
 
 
To investigate whether sideroblasts were present, we performed iron staining on the 
hematopoietic cells isolated from the methylcellulose cultures.  PS-iPS3 cells, which carry a 
significant burden of mutant mtDNA, yielded high numbers of erythroid precursors with 
pathologic iron granule deposition compared to PS-iPS cells with less mutant mtDNA (Figure 
2.10).  Collectively, these results demonstrate the recapitulation of a tissue-specific phenotype by 
directed differentiation of iPS cells carrying mutant mtDNA, and the amelioration of the 
phenotype in mutation-free, patient-identical iPS cells derived in vitro. 
 
Reprogramming cells from other patients with mtDNA deletion syndromes 
We obtained fibroblasts from two other patients suspected to have mitochondrial disease 
from the Coriell repository: one with symptoms consistent with Pearson syndrome (GM04516), 
and one with the later-onset variant Kearns-Sayre syndrome (GM06225).  We confirmed these 
clinical diagnoses by detection and mapping of mtDNA deletions in both lines (Figure 2.11 A).  
The burden of mutant mtDNA at a population level in the skin-derived fibroblasts was low: 6%  
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Figure 2.11, on following page: iPS lines from two other patients with mtDNA deletions.  (A): Detection of 
mutant mtDNA in cells from a Pearson syndrome patient (PS; GM04516) and a Kearns-Sayre syndrome patient 
(KSS; GM06225) by long range PCR.  The location of each mutation is illustrated in the schematic.  (B): 
Demonstration of pluripotency in iPS cell lines derived from PS (GM04516) and KSS (GM06225) by 
immunofluorescence and teratoma analysis (40-100x).  (C): PCR evaluation of iPS clones for the presence of the 
mutant species of DNA.  “Deleted” primers covered the deletion junction for each patient.  Patient fibroblasts (F) 
and lymphocytes (L) are included in multiples lanes as positive controls, all other lanes are individual iPS clones.  
Asterisk (*) denotes true positive, filled circle (•) denotes false positive, determined on subsequent testing.  61 
independent iPS cell clones were analyzed for PS (GM04516) and 21 independent iPS cell clones for KSS 
(GM06225). 
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Figure 2.11: iPS lines from two other patients with mtDNA deletions (Continued) 
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 for GM04516 and 3% for GM06225.  We reprogrammed these samples as described above and 
obtained with relatively high efficiency and normal kinetics several iPS cell lines bearing the 
hallmarks of pluripotency (Figure 2.11 B).  However, of the resulting lines, nearly none carried 
the mtDNA mutation: only 1 of 61 lines derived from GM04516, and 0 of 21 lines analyzed from 
GM06225 (Figure 2.11 C).  The reprogramming efficiencies and proportion of lines carrying the 
mtDNA deletion of samples from all three patients are documented in Table 2.1.  Collectively, 
these data demonstrate the efficient derivation of disease-free patient-specific iPS lines from 
patients with a low burden of a mosaic genetic abnormality.   
 
Table 2.1: Reprogramming kinetics and efficiency for three cell lines with mtDNA mutations.  
Cumulative results of at least three independent reprogramming experiments per cell line.  Pearson 
syndrome, PS; Kearns-Sayre syndrome, KSS. 
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Discussion and Future Directions 
 
Mitochondrial diseases are a unique category of genetic disorders.  Each cell contains 
tens or hundreds of copies of the mitochondrial genome, which are inherited randomly during 
cell division.  From a zygote that carries a mix of healthy and mutated mtDNA, random 
partitioning means that some tissues will be heavily affected by the mutation while others may 
show little or no defect.  Mitochondrial function varies widely in different cell types of the body 
and therefore mitochondrial disorders in patients manifest with myriad syndromes and 
conditions.  In the case of mtDNA defects, symptoms also depend on the deletion size and 
location, the severity of the heteroplasmy, and the mosaic of cell types affected.  Such 
heterogeneity makes mitochondrial disorders a challenge to diagnose, treat, and study.   
Most cellular research on Pearson syndrome, a rare multisystem mitochondrial DNA 
deletion disorder, has been performed in the cybrid system, where cytoplasts containing mutant 
mtDNA are fused to 0 nuclei from cancer cell lines.  But as can be predicted from using nuclei 
with vastly different cellular identities, cybrid systems are notorious for producing results that 
mimic the behavior of the 0 cell instead of the cell type affected by the disease (102, 103).  The 
advent of direct reprogramming technology has created new possibilities for the study of 
mitochondrial disorders by making it possible to study the mtDNA mutation in the relevant cell 
type. 
We have generated pluripotent stem cell lines by direct reprogramming of somatic cells 
from a patient with Pearson syndrome.  iPS cells carrying mutant mtDNA were derived with low 
efficiency and delayed kinetics, and showed impaired mitochondrial function and growth.  These 
PS-iPS lines were found to carry the mtDNA mutation.  During culture, heteroplasmy varied 
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between PS-iPS cell lines, allowing us to isolate pluripotent cells with the same nuclear genome 
but without mutant mtDNA.   
PS-iPS cells with and without the mtDNA deletion were differentiated towards the 
hematopoietic lineage in vitro and were capable of generating erythroid and myeloid colonies.  
Moreover, differentiation of cells from the PS-iPS line with the highest mutant mtDNA burden 
yielded erythroid cells with inappropriate iron deposits which are characteristic of Pearson 
syndrome.  The pathological finding of iron inclusions in erythroid progenitors is pathognomonic 
of the disease, suggesting that it arose from a disease-specific mechanism.  Thus, we were able to 
observe a mitochondrial disease phenotype in a cell lineage affected in the human disease. 
The study of mitochondrial disorders in iPS cells may also provide insight into 
mitochondrial function and mtDNA dynamics in stem cells in general.  Human pluripotent stem 
cells are reported to rely primarily on glycolysis for ATP production and to harbor immature, 
cristae-poor mitochondria (112-115).  Consistent with a relative lack of reliance on OXPHOS, 
we found that PS-iPS cells carrying high levels of deleted mtDNA could be generated and 
propagated.  However, the kinetics of iPS derivation from fibroblasts with high mutant mtDNA 
burdens were delayed, and growth of iPS colonies with high levels of mutant mtDNA was 
decreased.  Fibroblasts samples from two other patients generated iPS clones with normal 
kinetics and efficiency, and the resulting lines were free of deleted mtDNA.  This is likely due to 
low heteroplasmy in the initial fibroblast population but possibly also because of selection 
against clones carrying the mtDNA deletion.  Furthermore, in two of our PS-iPS lines, we 
observed a decline in heteroplasmy over time, suggesting that mutant mtDNA is selected against 
during rapid proliferation over many population doublings in the pluripotent state.   
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Given the inclusion of glucose in fibroblast and iPS culture medium, and the reportedly 
largely glycolytic state of human pluripotent cells (113, 115-117), these findings are somewhat 
unexpected and suggest that intact OXPHOS machinery may be required for optimal 
reprogramming of somatic cells and growth of pluripotent cells.  In keeping with these 
observations, a recent report shows that the OXPHOS machinery is active in pluripotent cells but 
uncoupled from ATP production, leading to speculation that mitochondrial activity is required 
for as yet undefined homeostatic functions in human pluripotent stem cells (118).  Moreover, our 
analysis of metabolism in PS-iPS cells showed a decrease in mitochondrial respiration in PS-iPS 
cells carrying high levels of mutant mtDNA compared to those without mutant mtDNA, 
revealing a basal level of oxidative activity that may serve a role in pluripotent cell homeostasis.  
The availability of isogenic iPS cells and derivatives carrying varying levels of deleted mtDNA, 
as described here, will provide a valuable platform to study the role of mitochondrial function in 
reprogramming of somatic cells, and growth and differentiation of human pluripotent cells. 
This work opens up many questions for future investigation.  Notably, in one of our PS-
iPS cell lines, mtDNA heteroplasmy was maintained at high levels over more than fifty passages 
(approximately 1 year) in culture.  Our observations are consistent with independent findings of 
variable heteroplasmy in iPS cells derived from patients with MELAS, a disorder caused by 
mtDNA point mutations (119).  We speculate that infrequent epigenetic or genetic changes, 
possibly including viral integrations, may enable rare iPS clones to tolerate heteroplasmy-
induced mitochondrial dysfunction.  Identification of these events could provide insights into the 
mechanism of disease and possibly inspire new treatments.  This question could be approached 
by investigating whether the integration sites of the reprogramming viruses in this line provide 
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insight into its tolerance of heteroplasmy, and to compare epigenetic profiles between lines that 
tolerate and do not tolerate heteroplasmy. 
In order for mtDNA disease iPS lines to eventually be used in a clinical setting, scientists 
will need to be able to control the fluctuation of heteroplasmy in culture.  We attempted multiple 
approaches to manipulate heteroplasmy (hypoxic culture, uric acid, rapamycin; data not shown) 
but were unable to identify culture conditions that affect heteroplasmy.  One possible approach 
would be to replace glucose in the media with galactose, which has been previously shown to 
select against cells with oxidative defects (120).   
Finally, it is interesting to consider that the observation of decreased heteroplasmy in 
rapidly-dividing pluripotent stem cells in vitro may be reflective of changes in mutant mtDNA in 
stem cells in vivo.  Pearson syndrome patients generally show spontaneous improvement in 
hematologic disease and immune function over the course of years, but worsening of neuropathy 
and myopathy (121, 122).  In patients with other mtDNA disorders, mutant mtDNA is found as 
the predominant species in post-mitotic skeletal muscle fibers, but depleted in mitotic cells such 
as blood cells and skeletal muscle satellite stem cells (123, 124).  Although the mechanisms 
driving these differences are largely unknown, selection against mutant mtDNA in dividing stem 
cells has been proposed as an explanation (121).  If similar forces are at work in the PS-iPS lines, 
further in vitro studies may yield insights into methods to promote the extinction of mutant 
mtDNA species in specific tissues in patients.  The PS-iPS cells we generated here could be the 
basis of a drug screen for previously-unknown compounds that promote extinction of 
heteroplasmy.  This type of screen could have wide-ranging clinical applications, as all cells in a 
patient's body would benefit from decreased heteroplasmy levels.   
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Conclusion 
 
This chapter describes the creation of iPS cells that carry varying burdens of mutated 
mtDNA from a patient with Pearson syndrome.  These isogenic lines provide a new tool for in 
vitro studies of mitochondrial dysfunction.  iPS cells offer a valuable complement to cybrid 
techniques because disease-carrying and disease-free iPS lines can be directly differentiated into 
specific tissue types to illuminate the pathophysiology of mtDNA disorders, and possibly to 
screen drugs that will support impaired cell-type specific functions.  Mutation-free iPS cells are 
also a potential source of healthy, autologous tissue-specific progenitors for patients with 
mitochondrial diseases, although significant hurdles remain in the translation of iPS based 
cellular therapy.  By exploiting their capacity for self-renewal and pluripotency, PS-iPS cells will 
be a valuable tool to understand tissue-specific pathophysiology and innovate treatments for 
patients with Pearson syndrome and other mitochondrial genetic disorders. 
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Chapter 3: Ring 14 Syndrome 
 
Introduction 
 
Ring 14 syndrome is a rare genetic condition, with fewer than one hundred cases 
diagnosed globally since its discovery in 1971 (125).  It occurs when the fourteenth chromosome 
is circularized, usually through loss of genetic material on both ends of the chromosome and 
subsequent end fusion via non-homologous end joining.  The ring 14 clinical syndrome typically 
presents with intellectual disability and severe drug-refractory epilepsy that begins within the 
first year of life, and it often associated with a distinctive facial appearance, retinitis pigmentosa, 
and microcephaly (126, 127).  Interestingly, epilepsy is also associated with ring chromosomes 
17, 18, 19, 20, and 21 (128-136). 
 
Mosaicism in ring 14 syndrome 
Many patients are mosaic for the ring chromosome: not all cells in their body contain the 
same genotype.  Ring 14 mosaicism occurs in two main types, which are reflective of the origin 
of the ring chromosome.  As a zygote, the majority of patients likely had one linear and one ring 
chromosome 14.  Upon development, the ring chromosome was present in every cell unless it 
was lost, so these patients are mosaic for ring 14 and monosomy 14.  In the smaller group of 
patients, the ring likely arose early in development but after the single-cell stage.  In this case, 
the patient is mosaic for ring 14 and disomy 14 and may thus have regions or even whole organs 
that do not carry the ring chromosome.  Interestingly, the only known ring 14 patient who does 
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not have severe intellectual disability falls into this latter category, suggesting the disomic 
mosaicism may have lessened the severity of the syndrome (42). 
 
Types of ring 14 chromosomes 
Ring 14 chromosomes are divided into three categories.  In some cases, only telomeric 
and nucleolar organizing sequences have been lost; these are said to be "complete" rings.  In 
others, more substantial coding regions are missing from the ring, resulting in "deleted" rings 
(137).  In still others, the rings exhibit a mixture of deleted and duplicated regions, termed 
"complex" ring chromosomes.  To investigate how the ring chromosome causes symptoms of 
ring 14 clinical syndrome, multiple groups have compared phenotypes between ring 14 patients 
with complete rings and deleted rings.  Developmental delay and drug-resistant focal epilepsy, 
the most severe symptoms of ring 14 syndrome, appear in all cases of ring 14 syndrome 
regardless of the category of ring chromosome.  On the other hand, the distinctive ring 14 facial 
appearance is associated only with deleted rings, specifically those with a deletion greater that 
0.65 Mb (42).   
 
Disease mechanisms in ring 14 syndrome 
The etiology of epilepsy in ring 14 syndrome is not yet understood.  The two most 
commonly proposed explanations are heterochromatin spreading on the ring chromosome 
causing functional neuronal haploinsufficiency of key chromosome 14 genes, and mitotic 
instability of ring chromosomes leading to epilepsy through an unknown mechanism (137).  
Unfortunately, due to the inaccessibility of affected neurons, researchers have been unable to 
investigate directly which explanation is responsible for the clinical findings.   
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In an attempt to distinguish between these two possibilities, researchers have compared 
the frequency of seizures between ring 14 patients and individuals who carry non-ring deletions 
on 14q.  Four groups have conducted such studies, and their combined findings show that 42% of 
patients with proximal 14q deletions, and 13% of patients with distal 14q deletions, suffer from 
seizures (126, 138-141).  The modest frequency of seizure in patients with linear 14q deletions 
could indicate that genes on 14q may be able to induce seizure upon haploinsufficiency, lending 
credence to the hypothesis that ring 14 syndrome epilepsy is caused by chromatin spreading, 
especially in proximal regions.  However, none of the studies found rates of seizure with deletion 
anywhere close to seizure frequency in ring 14 patients (average of 98%).  This, along with the 
preponderance of epilepsy in rings of other chromosomes, indicates that the presence of a ring 
chromosome itself may cause seizures.    
Ring 14 syndrome is so rare that comparison studies such as these are severely limited by 
the number of patients who partake, and so are unfortunately restricted in the conclusiveness of 
their results.  A more direct tool to analyze the function and behavior of ring 14 chromosomes in 
human neural cells would be more useful for understanding the mechanisms by which ring 14 
causes seizure.  Our goal in the study described here was to create such a tool. 
 
Generation of ring 14 iPS cells 
We reprogrammed cells from two ring 14 patients.  One starting sample was mosaic for 
ring 14 and disomy 14, and all of the resulting iPS lines from this patient demonstrated disomy 
14 with no ring chromosomes.  The other patient fibroblast sample was mosaic for ring 14 and 
monosomy 14.  All iPS lines derived from this patient carried the ring chromosome (R14-iPS).   
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We observed that over time in culture, the R14-iPS cells tended to lose the ring 
chromosome, while monosomic cells became more common.  R14-iPS cells with a high 
percentage of ring chromosomes were differentiated down a neuronal pathway, representing the 
first neural cells available for study from a ring 14 patient.  We were also fortunate enough to 
capture a nondisjunction event in one of the R14-iPS lines, resulting in a disomy 14 iPS line 
isogenic to the R14-iPS cells.  As this study continues, the isogenic disomic line will be used as a 
control to investigate the effect of the ring chromosome on neuronal differentiation. 
 
Materials and Methods 
 
Patient material 
The Galliera Genetic Bank (Galliera Hospital), member of the Network Telethon of 
Genetic Biobanks (Project No. GTB12001), funded by Telethon Italy and International 
Association Ring14 provided us with specimens. 
 
Cell lines and culture  
Ring 14 patient fibroblasts were grown in DMEM/10% FCS.  Media was changed every 
two days and cells were expanded by routine trypsinization and subculture.  iPS cells were 
grown either on irradiated murine embryonic fibroblasts (MEFs) with human ES media 
(DMEM:F12, beta-mercaptoethanol, glutamine, bFGF, and non-essential amino acids) or grown 
on matrigel and fed with mTeSR.  All medias contained 100 IU penicillin and 100 ug/mL 
streptomycin except where otherwise noted.  iPS cells were fed daily except for the day after 
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passage when they were left to sit undisturbed.  iPS lines were passaged by collagenase while on 
MEFs or dispase while on matrigel, and picked by hand when necessary. 
 
Reprogramming of ring 14 patient samples 
Cells were reprogrammed using the three Yamanaka episomes, each with two genes on 
the pCXLE vector: OCT3/4 and sh-p53; SOX2 and KLF4; LIN28 and L-MYC.  These were 
prepared using endotoxin-free megapreps (Qiagen).  Fibroblasts were trypsinized and counted.  
500,000 cells of each line were spun down.  The Amaxa nucleofection kit was utilized as 
described by the manufacturer, using program p-022 for the nucleofection.  After nucleofection, 
the cells were placed in one well of a 6-well plate, in antibiotic-free DMEM/10% FCS media.  
Media was changed the following day to include antibiotics.  On day 6 after nucleofection, the 
wells were split onto MEFs at two ratios: 1:36 and 5:36.  The day following the split, the media 
was changed to hES media and fed daily hES until picking.  From days 20 - 25, iPS colonies 
were identified and picked by hand into 6-well plates with MEF feeders.  Picking was done in 
hES media containing 10 uM compound Y-27632 (Sigma) to prevent apoptosis.  Picked colonies 
were passaged by hand with individual colony cutting.  Ten iPS lines were established from 
Patient 1 (R14-iPS lines 1 - 10, seven of which were eventually karyotyped), and eight from 
Patient 2 (R14-iPS lines A - H, five of which were eventually karyotyped).   
  
G-banded karyotyping 
Cells were plated on MEFs in T25 dishes 2-4 days before submission for karyotyping.  
All G-banded karyotyping was performed by Cell Line Genetics.  Unless otherwise stated, 20 
cells were counted in karyotype. 
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Fluorescent in situ hybridization (FISH) 
Cells were plated in T25 dishes 2-4 days before submission for FISH.  FISH was 
performed by Cell Line Genetics, using probes for the telomeres and a probe for part of 
chromosome 14 present in both the linear and ring chromosome.  The pattern of telomere and 
non-telomere probe allowed for distinction between disomic, monosomic, and ring 14 cells.  
Unless otherwise stated, 20 cells were counted in each FISH assay. 
 
Microsatellite analysis 
DNA was collected from iPS cell lines grown on matrigel.  Samples were submitted to 
the Centre for Applied Genomics at the Hospital for Sick Children in Toronto, Canada for 
analysis.   
 
Immunostaining of iPS cells 
Performed as described in Chapter 2. 
 
Subcloning of R14-iPS cells 
In order to create clonal R14-iPS lines, with specific karyotypes, R14-iPS line E was 
incubated in hES media containing 10 uM compound Y-27632 (Sigma) for 30 minutes, then 
washed with DMEM:F12 and treated with accutase at 37 degrees for 15 minutes, with occasional 
pipetting.  Cells were strained through a 40 um filter, then spun down.  After being resuspended 
in hES with Y-27632, the cells were strained again, resulting in a suspension of single cells as 
verified on a microscope.  These cells were plated at low density (15 - 100 cells per cm2) on 
MEFs and returned to the incubator.  48 hours later they were fed regular hES media, then media 
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was changed every day following.  Very small colonies began to appear 7 days after splitting, 
and most were large enough to pick by day 12 - 14.  Colony picking proceeded by hand as 
described above. 
 
Neural induction and maturation of R14-iPS cells 
Neural differentiation was performed by dual SMAD inhibition as described previously 
(142, 143).  In short, R14-iPS cells were plated as single cells in mTeSR1 media.  They were 
treated with Noggin (R&D/Peprotech) or ALK2/ALK3 inhibitor LDN-193189 and SB431542 
(Tocris Bioscience) in knockout serum replacement based media and they were transitioned into 
N2 media (Neurobasal with 0.5x B27, 1x N2 and 2 mM Glutamax) over ten days.  Following 
dual SMAD inhibitor treatment, cells were passaged and expanded in N2 media with bFGF (Life 
Technologies).  Neural rosettes were imaged on day 29 of differentiation.  Neural progenitors 
were imaged on day 34 of differentiation after the cell mixture was depleted of neural crest cells 
by CD271 microbeads (Miltenyi) and enriched for PSA-NCAM+ cells. 
 
Studies and Results 
 
Comparison of ring 14 mosaicism between two patients 
In order to distinguish between the effect of the ring and the effects of deleted coding 
sequences, we chose to create iPS cells only from patients that carried non-deleted rings.  We 
obtained dermal fibroblasts from two patients with ring 14 syndrome.  In both patients, the 
chromosomal breakage and rejoining occurred between 14p12 and 14q32.3 (Figure 3.1 A).  As 
measured by karyotype, the sample from Patient 1 contained 4% ring 14 and 96% disomy 14,  
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Figure 3.1: Fibroblasts from two patients with ring 14 syndrome.  (A) Both patients have complete rings, 
with breakpoints at 14p12 and 14q32.33.  (B) Patient 1 fibroblast karyotypes.  (C) Patient 2 fibroblast 
karyotypes.  (D) Brightfield image of Patient 1 fibroblasts (40x).  (E) Brightfield image of Patient 2 fibroblasts 
(40x). 
 
while the sample from Patient 2 carried 86% ring 14 and 14% monosomy 14 (Figure 3.1 B and 
C).  Both fibroblast samples grew normally (Figure 3.1 D, E). 
 
Generation of iPS cells carrying a ring chromosome 14 
After confirming the presence of the ring, we initiated reprogramming.  500,000 
fibroblasts were nucleofected with reprogramming episomes containing OCT3/4, KLF4, SOX2, 
MYC, LIN28, and sh-p53.  Reprogramming proceeded normally and colonies were picked around 
three weeks after nucleofection (Figure 3.2 A).  Out of seven iPS lines assayed from Patient 1, all 
were disomic and none carried the ring chromosome.  On the other hand, all of the five tested  
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Figure 3.2: iPS cells carrying ring chromosome 14 from Patient 2.  (A) Brightfield image of a R14-iPS 
colony grown on MEFs (40x).  (B) R14-iPS cell karyotype.  (C) Visualization of the ring chromosome in an iPS 
cell by fluorescent in situ hybridization.  The red probe hybridizes to 14q13.1, which is present in both the ring 
and the linear chromosome.  The green probe hybridizes to 14q32.33 sequence beyond the breakpoint, so is not 
present in the ring chromosome.  (D) Immunofluorescence staining for human pluripotency markers (100x).  (E) 
Teratomas from R14-iPS lines show differentiation into all three germ layers. 
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iPS lines derived from Patient 2 carried ring chromosome 14 (Figure 3.2 B).  We were able to 
visualize the ring chromosome in the pluripotent cell using fluorescent in situ hybridization 
(FISH) with probes against chromosome 14 telomeric sequence and a region of chromosome 14 
present on both the ring and the linear chromosome (Figure 3.2 C).  Although these numbers are 
small, they are consistent with the hypothesis that cells with disomy 14 reprogram better than 
cells with ring 14, which in turn fare better than cells with monosomy 14. 
Of the five iPS lines from Patient 2 that carried the ring chromosome, three were selected 
for further characterization.  R14-iPS cells were positive for pluripotent cell surface markers 
including NANOG, SSEA4, TRA160, OCT4, and SSEA3, and were able to form teratomas that 
contained cells from all three germ layers (Figure 3.2 D, E).  These results show the derivation of 
human iPS cells carrying a ring chromosome 14. 
 
Changes in R14-iPS karyotype over time 
Given that the frequency of ring chromosomes may change over time in vivo, we 
wondered whether the iPS cells would show a selection against the ring during in vitro culture.  
We karyotyped the R14-iPS lines at passage 3 and again at passage 15 or 17 (Figure 3.3).  Two 
of the lines displayed the behavior we had expected: early passage cultures carried the ring  
 
 
 
 
Figure 3.3: R14-iPS karyotype dynamics.  Changes in chromosome 14 karyotype status over approximately 
three months in culture.  "Abnormal" refers to a karyotype that contains translocations or chromosomal loss or 
gain.  These aberrations are often associated with enhanced growth in vitro.   
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Figure 3.4: Spontaneous uniparental disomy.  (A) Karyotype of spontaneous disomy in a ring 14 patient-derived 
iPS cell.  (B) Visualization of disomic chromosome 14 in an iPS cell by fluorescent in situ hybridization.  (C) 
Genotyping analysis of six microsatellite markers along chromosome 14 confirms uniparental disomy.  Each bar 
represents one allele from that sample. 
 
 
chromosome in every cell, but over the three months of passage, ring chromosomes were slowly 
lost and monosomic cells (or karyotypically aberrant cells) became more prevalent.  One R14-
iPS line manifest a less stable karyotype during early passage in which ring 14, monosomy 14, 
and aberrant chromosomes were all strongly represented.  After continued cell culture, the 
karyotype normalized.  The percentage of ring and monosomic chromosomes were unchanged, 
while the aberrant karyotype population was completely replaced by a novel species: cells 
disomic for normal chromosome 14 (Figure 3.4 A).   
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Isolation of a disomic control line 
The ideal control for experiments testing the behavior of R14-iPS cells would be an iPS 
line isogenic to the R14 line, but carrying disomy 14 instead of a ring.  This would allow for 
experimental comparisons in which the only difference between inputs would be the presence or 
absence of the ring; the cell line and the DNA gene dosage would be the same between both 
conditions.  Any observed phenotypic differences could then be immediately ascribed to the 
presence of the ring chromosome.  In pursuit of such a line, we subcloned the R14-iPS cells that 
showed spontaneous disomy, and we were able to isolate a line that carried exclusively disomy 
14 (Figure 3.4 B).  PCR analysis of microsatellites on chromosome 14 confirmed that the second 
copy of linear chromosome 14 arose from spontaneous uniparental disomy (Figure 3.4 C). 
All told, we observed five species of chromosome 14 in our iPS cells (Figure 3.5).  Not 
only did we see monosomy and disomy, but also a double ring (twice the genetic material of a 
normal ring) and a species with one linear chromosome and two discrete rings.  These findings 
underscore the mitotic instability of the ring chromosome. 
Figure 3.5: Genomic instability of the ring chromosome.  We observed five species of chromosome 14: (A) 
Ring 14 (B) Monosomy 14 (C) Disomy 14 (D) Double ring 14 (E) One linear, two rings 14.  
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Figure 3.6: Neural differentiation schema.  
 
Neural differentiation of R14-iPS cells 
As ring 14 syndrome's primary symptoms affect the central nervous system, we decided 
to differentiate the R14-iPS down a neural pathway.  The dual-SMAD inhibition protocol is 
illustrated in Figure 3.6.  R14-iPS cells were able to form neural progenitor cells, neural rosettes, 
and cells with neuronal morphology that stained positive for the neuron-specific marker beta III 
tubulin (Figure 3.7).  As our investigation continues, we will differentiate the R14-iPS and the 
disomic control line in parallel and perform more extensive characterization of the resulting 
cells.  This will provide insight into the effect of the ring on neuronal development. 
Figure 3.7: Neural cells derived from R14-iPS.  R14-iPS cells of origin carried about 70% ring chromosome, 
30% monosomy.  (A) Neural progenitor cells.  (B) Neural rosettes.  (C) Cells with neuronal morphology.  (D) 
Neural cells stained for Hoechst (blue) and neuron-specific beta III tubulin (green). 
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Discussion and Future Directions 
 
Of the three disorders described in this dissertation, the least is known about ring 14 
syndrome.  The complete inaccessibility of brain cells has prevented researchers from 
investigating even the most basic questions about how such a drastic chromosomal disturbance 
manifests itself as epilepsy and developmental delay.  Two hypotheses are frequently discussed 
in the literature to potentially explain the ring 14 phenotypes: the spreading of centromeric 
heterochromatin to compromise haploinsufficient genes, and the presence of the ring 
chromosome itself.  Evidence for the former possibility lies in the genes present near the 
centromere after chromosome 14 circularization: DICER, IGH, FOXG1, and a large microRNA 
cluster.  Evidence for the latter possibility comes from the presence of seizures in patients with 
other ring chromosomes (128-136). 
So far, scientists have only had a single analytical tool to bring to bear on this question: 
phenotypic comparisons between patients with various sizes and locations of genetic deletions, 
with or without a ring chromosome.  Unfortunately, the small size of these studies has prevented 
them from reaching any definitive conclusions about how the ring chromosome 14 leads to 
developmental delay and seizure.   
Our work here has created iPS lines that carry a ring chromosome 14.  Fibroblasts from a 
patient mosaic for ring and disomy 14 yielded only iPS lines with two normal copies of 
chromosome 14, while fibroblasts from a patient mosaic for ring and monosomy 14 
reprogrammed exclusively into pluripotent cells that carried the circularized chromosome.  The 
R14-iPS cells grew normally in culture, and over time we noticed a tendency for the ring 
chromosome to be lost, much as has been previously documented in patients.  We differentiated 
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R14-iPS cells carrying the ring chromosome down a neural lineage and observed neural rosettes 
and neuronal morphology.   
As expected, the ring 14 lines demonstrated mitotic instability.  Five different 
arrangements of chromosome 14 were observed during our study, including the appearance of 
normal, disomic cells in one iPS line.  After this unexpected finding, we were able to isolate iPS 
cells that differed only in their chromosome 14 genotype: ring or disomy. 
The appearance of a disomic subpopulation of cells in our culture was surprising.  These 
46, XY cells could not have arisen from a small population in the starting fibroblasts, because 
each iPS line is derived from a single reprogrammed cell.  Therefore, the disomic cells must have 
been generated during in vitro culture.  Since regions of the teleomeres and nucleolar organizing 
regions are deleted in the ring chromosome, it is implausible that the second linear copy of 
chromosome 14 could result from a ring opening.  This is underlined by microsatellite analysis 
demonstrating that the two linear chromosomes are derived from uniparental disomy.  This 
finding confirms that a nondisjunction event occurred, resulting in a duplication of the entire 
non-ring chromosome.  We suspect that this event occurred in a monosomic cell, as there is no 
evidence of cells with two linear chromosomes and one ring, but we cannot rule out this 
possibility.  The 46, XY clone's ascendance suggests that disomic iPS cells enjoy a selective 
advantage over those carrying the ring chromosome.   
After we observed dynamic karyotypes and disomy appear in our culture, a paper was 
published in Nature in March of this year that reported findings highly similar to ours, albeit on 
different ring chromosomes.  Bershteyn et al. generated iPS cells from a patient with ring 
chromosome 17 (144).  They found that the ring chromosome was quickly lost with passage.  
The selection against ring chromosome 17 in the iPS cell stage was much stronger than the 
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selection we observed against ring chromosome 14, as they did not even find the ring in some of 
the initial lines they examined.  After documenting the disappearance of the ring chromosome 
17, the authors observed appearance of a disomic population and confirmed its origins as 
uniparental disomy.  They then repeated the experiments in cells containing ring chromosome 
13, and found much the same results.  
The Bershteyn et al. paper suggests that our findings of ring chromosome 14 dynamics in 
iPS cells are likely to be generalizable to all ring chromosomes.  While being upstaged by such a 
publication is a risk of working in a fast-moving and exciting field, the paper did not make any 
effort to differentiate the iPS lines into the cell types affected by the disorders.  We anticipate 
extending our studies to include such differentiations prior to submission of our manuscript.  We 
have already generated neuronal cells from a R14-iPS line, and now that we have isogenic lines 
from a ring 14 patient that differ only in the presence or absence of the ring chromosome, we are 
poised to make the next step.  As we did in Pearson syndrome, the next project in this disease 
will be to differentiate both the R14-iPS and the disomic iPS into the cell type most strongly 
affected by the disease—in this case, neurons.  We will compare differentiation efficiency at 
each step of the process.  Since some types of epilepsy are attributable to an imbalance of 
glutamatergic and GABAergic neurons in the central nervous system, we will investigate 
whether the R14-iPS cells produce a skewed ratio of Glu:GABA neurons upon differentiation.  It 
is our belief that this differentiation data will give our data a high impact, complementing the 
recent Nature paper.   
There are three exciting future directions for this project.  The first is described above, 
differentiation of the cells into neurological cells and investigation of the GABAergic and 
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glutamatergic neuron populations.  We expect to accomplish this goal before the paper will be 
submitted in the next few months.   
The next exciting investigation for this project would be based on recent work in Dravet 
syndrome.  Dravet syndrome is a severe epilepsy condition caused by de novo mutations in the 
voltage-gated sodium channel gene SCN1A.  As a channelopathy, it was the first epilepsy 
syndrome to be studied in human iPS cells.  Three different research groups published patient-
specific iPS cell-based models of Dravet syndrome in 2013 (145-147).  Each group generated 
iPS cells from patients with Dravet syndrome, then differentiated them into neurons and 
attempted to identify electrophysiological phenotypes in the resulting cells.   
Before these studies were released, all previous work in mouse models, 
electrophysiological studies in Xenopus, and overexpression assays in human cell lines agreed 
that SCN1A mutations uniformly led to reduction in sodium currents.  Thus, the reigning 
mechanistic explanation was that SCN1A mutations caused epilepsy by impairing firing efficacy 
of GABAergic interneurons.  The recent work in iPS cells revealed a very different story, and 
underscores the impact that cell type can have on the phenotype of a given genetic mutation.  
The three Dravet iPS modeling papers suggest that SCN1A mutations actually fall into two 
distinct categories with completely different disease mechanisms.  The first type of mutation 
indeed impairs action potentials in GABAergic neurons (145).  But the second, and more 
common type, in fact increases sodium currents by 2-3 fold in both glutamatergic and 
GABAergic neurons (146, 147).  These findings revolutionized scientists' understanding of 
Dravet syndrome and demonstrate the vital importance of studying genetic mutations in the 
appropriate cell type.   
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In addition to gaining insight into the mechanism of Dravet syndrome, these papers 
demonstrate that electrophysiology can be used to investigate genetic epilepsy syndromes on a 
single-cell level.  Once neurons have been generated that contain ring chromosome 14, it will be 
fascinating to investigate their electrophysiological properties on the cellular level.  Whole-cell 
current clamp measurements can be used to investigate cellular response to stimulation, and 
voltage clamp assays can provide information about the number and type of voltage-gated ion 
channels present in the cells.  Expansion of heterochromatin is a cell-autonomous process, and if 
it is the main cause of seizures in ring 14 syndrome, we would expect to see electrophysiological 
differences between R14 and WT neurons.  Effects of a ring chromosome on cell division and 
mitotic stability, on the other hand, are more likely to manifest as cellular disorganization or 
impairment of cellular connection.  If these are the main causes of R14 epilepsy, we would 
expect to observe phenotypes on the population level, not on a cell-autonomous scale. 
The third exciting research prospect would be to break open the ring chromosome using 
genome editing techniques.  This could be accomplished using CRISPR/Cas9 technology to 
introduce a double strand break in the ring chromosome, then adding telomeric sequence to the 
break site either by homologous recombination or by capitalizing on the cell's propensity for 
NHEJ-based repair.  If ringbreaking were successful, this cell line would be an excellent addition 
to the model.  It would allow us to distinguish more precisely between phenotypic effects caused 
by the presence of the ring, heterochromatin disparities between ring and linear chromosomes, 
and the effect of genetic material lost during ring formation. 
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Conclusion 
 
Understanding the pathophysiology of inborn genetic disorders requires a research tool 
that allows researchers to study the disease in the affected cell type.  The complete inaccessibility 
of brain tissue has prevented scientists from investigating even the most basic questions about 
how ring 14 and other ring chromosomes manifest as treatment-resistant epilepsy, so the goal of 
our study was to produce neural cells from a patient with ring chromosome 14.  We have 
accomplished that goal.  These cells will provide researchers with a new tool to investigate the 
etiology of seizure and developmental delay in ring 14 syndrome, and especially to determine the 
relative importance of heterochromatin spreading and ring effects for these symptoms.    
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Chapter 4: Fanconi Anemia 
 
Introduction 
 
Fanconi anemia (FA) is the most common inherited cause of bone marrow failure.  
Mutations in any of more than a dozen genes can cause the same clinical picture, including 
skeletal abnormalities, cancer predisposition, and bone marrow failure.  Bone marrow failure is 
in a rare class of disorder: those that could, one day, be cured by a transplant from a patient's 
own iPS-derived cells.  In fact, because the liquid blood organ needs no matrix, organization, or 
shape, many researchers believe that iPS-derived cellular therapy will be more feasible in the 
blood system than in some other organs.  With the goal of cell therapy in mind, when 
laboratories across the globe were first reprogramming cells from patients with all kinds of 
disorders, many groups attempted to reprogram cells from FA patients.  None were successful. 
Why not?  We have investigated this question with multiple experimental approaches and 
have numerous interesting findings, but a single comprehensive explanation is still evasive.  It 
was our initial belief that FA cells' inability to reprogram suggested a fundamental role for the 
Fanconi DNA repair pathway in the reprogramming process.  Our results call this hypothesis into 
doubt, and suggest that perhaps the FA proteins are required for an earlier step in the process 
than we had anticipated.  We hope that the work described in this chapter will contribute to the 
eventual solution of the puzzle. 
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Molecular phenotype of Fanconi anemia 
Fanconi anemia is a clinical syndrome that can be caused by homozygous mutation of 
any of fifteen different genes, named FANCA, FANCB, FANCC, etc.  Most of these genes are 
located on autosomal chromosomes, and so demonstrate an autosomal recessive inheritance 
pattern, although FANCB is on chromosome X and manifests accordingly.  About 66% of 
Fanconi anemia is caused by mutations in FANCA, followed by about 12% each in FANCC and 
FANCG (148).  The rest of the genes combine to comprise the other 10% of cases.  The cause of 
this unequal distribution is not well understood, although the FANCC mutation is associated with 
the Ashkenazi population and so is more common in that group (149). 
 The FA proteins are members of a DNA repair pathway responsible for removing 
accidental covalent crosslinks between DNA strands.  First, FANCM identifies the presence of 
DNA crosslinks and causes assembly of eight FA proteins into the FA core complex (150, 151).  
The core complex then ubiquitinates FANCD2 and FANCI, which form a heterodimer (152).  
This heterodimer directs a nuclease to induce a double strand DNA break at the site of the 
crosslink, and the FA complex oversees translesion synthesis and homologous recombination to 
repair the break (153).  Mutation of any single FA protein prevents the pathway from resolving 
DNA crosslinks, which is believed to be the reason that mutations in many different genes result 
in such similar clinical syndromes. 
In the laboratory, mitomycin C or nitrogen mustard are commonly used to induce 
crosslinks for investigation.  But the primary source of DNA crosslinks in a physiological setting 
has been hard to identify.  Recent studies have used double knockout animals to investigate 
which pathways are cooperative with FA.  Interestingly, animals missing a Fanconi gene are 
highly sensitive to loss of a gene responsible for breaking down aldehydes (154).  Aldehydes are 
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common products of metabolism and are also encountered in the environment.  They are highly 
reactive moieties that can form DNA adducts and cause crosslinks (155).  The importance of this 
pathway in clinical Fanconi anemia was underscored by a recent investigation in Japan, where 
mutations in acetaldehyde dehydrogenase are common.  Patients who suffered mutations in both 
pathways showed more severe phenotypes, including bone marrow failure within the first few 
months of life (156).  These studies support endogenous aldehydes as a leading cause of 
genotoxcicity in FA patients.   
 
FA clinical syndrome 
Fanconi anemia is usually diagnosed in the first decade of life, although rare patients 
have been diagnosed in their thirties or later (157, 158).  About two-thirds of patients are 
diagnosed soon after birth due to skeletal abnormalities, including thumb hypoplasia and 
congenital scoliosis.  The remaining 1/3 are usually diagnosed upon hematological involvement 
(159).  Pancytopenia usually begins to occur around age seven and soon progresses to full bone 
marrow failure, frequently converting to myelodysplastic syndrome or acute myeloid leukemia.   
Given the inexorable progression towards bone marrow failure, physicians begin looking 
for an HLA-match as soon as patients are diagnosed with FA.  Unfortunately, less than a quarter 
of all FA patients have access to a matched, unaffected sibling donor, and many pass away from 
bone marrow failure or failure of an unrelated bone marrow transplant (160).   
In addition to skeletal abnormalities and hematological complications, FA is a cancer 
predisposition syndrome.  As the FA pathway is required at the molecular level to repair DNA 
damage, mutation in a FA gene causes DNA mutations and chromosomal abnormalities to 
accumulate over time.  The cumulative risk of cancer (leukemia or solid tumor) in a FA patient is 
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about 40% by age 48 (161, 162).  Part of this risk is caused by the bone marrow transplants that 
most patients experience in their youth; Fanconi patients are uniquely sensitive to many of the 
drugs used in conditioning regimens, increasing their chances of later malignancies. 
 
Attempts to reprogram: the FA reprogramming defect 
In 2008 our laboratory, while successfully using viruses to reprogram cells from patients 
with ADA-SCID, Gaucher disease, Duchenne and muscular dystrophies, Down syndrome, 
Parkinson disease, Diabetes type I, Swachman-Bodian-Diamond syndrome, and Huntington 
disease, tried to reprogram cells from six different FA patients (10).  None were successful 
(Table 4.1).  The following year, the Belmonte group in Spain published their work in FA 
reprogramming.  They found that cells from Fanconi patients could be reprogrammed into iPS 
lines, but only if the gene defect was corrected before reprogramming began.  They were unable 
to reprogram any somatic cells carrying a defective FA pathway into expandable iPS lines (163).   
In 2012, Dr. David Williams published an extensive study of reprogramming in FA 
mouse cells (164).  They found that FA cells could be reprogrammed using viruses, but at greatly 
reduced efficiency compared to wild-type cells.  The authors identified elevated levels of 
gamma-H2AX in the FA cells after infection, and suggested that there may be a threshold level 
Table 4.1: FA cell lines for which reprogramming was attempted during preparation of our laboratory's 
2008 Cell paper. 
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of acceptable gamma-H2AX for reprogramming.  However, infection caused the gamma-H2AX 
levels to increase by the same amount in both FA and WT cells.  This finding suggested that the 
observed higher levels of gamma-H2AX after infection are due to baseline differences, not 
reprogramming.  If a threshold is indeed involved, it is not mediated through p53 pathways, as 
the authors observed no difference in p53, p21, or p19 levels between WT and FA cells during 
reprogramming.  Thus, the cause of the FA reprogramming defect is still unclear. 
 
Hypothesized role of FA proteins in reprogramming 
The reprogramming cocktail contains powerful transcription factors.  Two of them, KLF4 
and MYC, are notorious oncogenes.  It is well documented that expression of OCT4, SOX2, 
KLF4, and MYC results in genomic trauma, especially double strand breaks (DSBs) in DNA 
(164-166).  The cell has two main ways of repairing DSBs: homologous recombination (HR), 
which is highly accurate, and the more error-prone non-homologous end joining (NHEJ).  In 
wild-type cells, HR is employed whenever possible in order to avoid mutations caused by NHEJ 
(167).  But in Fanconi cells, NHEJ has been shown to be aberrantly hyperactive, resulting in 
DNA damage and chromosomal breakage (168, 169).  This suggests that FA proteins are 
responsible for prioritizing HR over NHEJ when the cell chooses a repair pathway.  Thus, in 
cells where the FA pathway is non-functional, DNA damage accrues not only through failure to 
repair crosslinks, but also through inappropriate choice of NHEJ over HR.   
When genomic damage is found in a cell, whether in the form of DSBs or replication 
forks stalled at DNA crosslinks, cellular signaling prevents further cell division until the damage 
has been repaired.  These signals include activation of the p53 and Chk1/2 pathways.  Although 
the role of Chk1/2 in reprogramming has not been studied, p53 is known a strong inhibitor of the 
 72
process (170-172).  Together with the role of FA in controlling DNA repair, this information led 
us to form the following hypothesis to explain the FA reprogramming defect: expression of 
OSKM induces DNA breaks.  In normal cells, the FA proteins help ensure they are repaired via 
HR, but in Fanconi cells, overactive NHEJ results in increased genomic damage.  This, along 
with the initial damage, activates DNA damage signaling pathways, which in turn prevent 
reprogramming.   
 
Materials and Methods 
 
Generation of the reprogrammable FANCC-/- mouse (Figure 4.3) 
We purchased mouse stock number 011004 from the Jackson Labs.  This mouse was 
homozygous for two transgenes: the reprogramming factors OCT4, SOX2, KLF4, and MYC 
integrated at the COL1A1 locus under control of the dox responsive element, and rtTA integrated 
at Rosa26.  Together, we refer to these two transgenes as "inducible OSKM" or "iOSKM."  We 
obtained FANCC-/- mice through a kind gift of Dr. David Williams.  The FANCC-/- mice were 
bred with the 011004 mice to create triple heterozygous transgenics.  Because FANCC-/- mice 
suffer from impaired fertility, we bred the heterozygotes back with the iOSKM mice to obtain 
mice homozygous for iOSKM and heterozygous for FANCC.  These mice were then bred to each 
other to produce embryos for MEF derivation: approximately one quarter of the resulting 
embryos were WT for FANCC, and one quarter were FANCC-/-.  These littermates were 
compared in all reprogramming experiments. 
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Murine Embryonic Fibroblast (MEF) collection 
iOSKM, FANCC+/- mice were set up in timed matings and checked for plugs the 
following morning, then removed from the male's cage.  On day 13 or 14 after mating, females 
were palpated to determine pregnancy.  Pregnant females were sacrificed according to our 
laboratory's animal protocol.  The uterine horns were removed and placed in a dish of PBS with 
penicillin and streptomycin on ice.  In a tissue culture hood, the embryos were removed from the 
uterus and dissected out of its membranes and placenta.  With multiple PBS rinses, forceps were 
used to isolate the torso and limbs, the main sources of embryonic fibroblasts.  Mechanical and 
enzymatic (trypsin, collagenase IV, hyaluronidase V, and DNAse) methods were used to reduce 
the tissue to single cells.  These were then put through a 40 um sieve and plated in DMEM/10% 
FCS media, one embryo per 10-cm tissue culture dish.  These MEFs were then expanded and 
passaged as usual fibroblasts.  During dissection, extra tissue from each embryo was placed into 
lysis buffer for genotyping.   
 
Collection of fibroblasts and keratinocytes from neonatal mice 
Neonatal mice were anesthetized with CO2 and then sacrificed.  Pup bodies were 
submerged in 70% ethanol for 15 seconds to decontaminate them, then rinsed in PBS.  Feet were 
removed and used for genotyping.  An incision was made along the back, allowing the skin to 
separate from the body wall.  The skin sheet was then rinsed in PBS and transferred into dispase, 
where it sat overnight at 4 degrees.  The next day, excess dispase was washed off and then 
forceps were used to pull apart the epidermis from the dermis with forceps.  Neonatal fibroblasts 
come from the pink dermis, while the white epidermis is the source of keratinocytes.   
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Keratinocytes: the epidermis was transferred into TrypLE Select (Invitrogen) with basal 
layer facing down, and incubated 20 - 30 minutes at room temperature.  CnT media (Cellntech) 
was added, the epidermis was mechanically agitated in order to loosen the keratinocytes.  After 
collecting all cells, they were seeded at 40,000 cells per cm2 in CnT media, in flasks coated in 
retronectin.  Media was changed every other day.  Keratinocytes were reprogrammed in the same 
fashion as fibroblasts (see below), except in CnT media instead of DMEM/10% FCS. 
Fibroblasts: the dermis was transferred into 0.25% trypsin and incubated at 37 degrees for 
10 minutes.  The cells were spun down and resuspend in DMEM/10% FCS medium.  Media was 
changed every other day.   
 
Reprogramming blood 
Retro-orbital bleeds were used to collect 100 uL of peripheral blood per mouse as 
described in our animal protocol.  Reprogramming of blood cells was performed as described by 
Stadtfeld et al. (173). 
 
Reprogramming iOSKM FANCC+/+ and FANCC-/- MEFs 
Five independent reprogramming experiments were completed comparing littermate 
animals with varying Fanconi C genotypes.  They are described here by their labels in Figure 
4.5.  In experiment B, 100K cells per replicate were reprogrammed.  At the split on day 3, 50K 
cells were plated per technical replicate.  In experiment C, 100K cells per replicate were 
reprogrammed.  All wells were split 1:4 on day 3.  In experiment D, 600K cells per replicate 
were reprogrammed.  At the split on day 3, 15K cells were plated per technical replicate.  In 
experiment E, 40K cells per replicate were reprogrammed.  At the split on day 3, 15K cells were 
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plated per technical replicate.  In experiment F, 100K cells per replicate were reprogrammed.  At 
the split on day 3, 15K cells were plated per technical replicate.  Cells were fixed on day 24 - 28 
and stained for SSEA1.  Stained plates were scanned, and colony counts were performed by 
ImageJ analysis.   
 
Calculating reprogramming efficiency: colonies per original input cell  
On day 3 during murine reprogramming, the cells are trypsinized, counted, and re-plated 
onto feeders.  Because some input cells grow more quickly than others, each line has a different 
total number of cells by day 3 after reprogramming has begun.  In most of our experiments, we 
plated the same number of cells onto feeders on day 3 for all of the reprogramming lines, 
regardless of how many cells were present.  We found that this approach of normalizing the 
number of cells plated on day 3 was superior to its alternative (a fixed split ratio), because it 
usually resulted in similar fibroblast growth and colony density per well by the end of the 
experiment.   
For example, cell lines A and B both may have 40K input cells plated on day 0.  These 
would receive doxycycline for 3 days, then be trypsinized and counted.  Line A may have a total 
of 300K cells, while line B may have a total of 150K cells.  Each of these lines would be plated 
in triplicate, with 15K cells per well of a 6-well plate.  The excess cells would be discarded.  This 
approach introduces a split factor: line A was split 1:20, and line B was split 1:10.  If the average 
number of colonies in the line A wells is equal to that of the line B wells, we would conclude 
that line A reprograms with twice the efficiency of line B.   
To calculate the number of colonies per input cell, one must first extrapolate the total 
number of colonies that the line would have produced if all of its day 3 cells had been plated at 
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the target density (and not discarded).  This can be calculated by dividing the average colonies 
per well by the number of cells plated per well on day 3.  This number is then multiplied by the 
total number of cells present in that line on day 3, whether or not they were actually plated. 
 
Extrapolated total  = Average colonies per well * Total number of cells on day 3 
number of colonies    Cells plated per well on day 3    
 
The extrapolated total number of colonies, divided by the number of input cells, provides the 
most basic "colonies per input cell" measure that is used in the left-hand panels of the efficiency 
figure. 
 
Colonies per  =  Average colonies per well * Total number of cells on day 3 
input cell Cells plated per well on day 3 * Number of input cells   
 
 
Calculating reprogramming efficiency: colonies per cell plated on day 3 
As described in the text, measuring colonies per input cell can bias reprogramming 
efficiency towards input cell lines with high proliferation rates.  To minimize this effect, we also 
report the average number of colonies per cell plated on day 3.  This is a much more 
straightforward measure: 
 
Colonies per plated     =      Average colonies per well    . 
day 3 cell  Cells plated per well on day 3 
 
Because no cells are discarded in this measure, it is not an extrapolated number.  This measure is 
reported in the right-hand panels of the efficiency figure.   
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Reprogramming samples from human Fanconi patients 
Cells from two FA patients were a kind gift from Dr. Alan D'Andrea's laboratory.  Both 
samples grew well as fibroblasts and were reprogrammed by episome and iPS lines established 
as described above in Chapter 3.   
 
Western blotting of FANCD2 
Mouse-anti-human FANCD2 antibody FI17 was used at 1:1000 (Santa Cruz).  Mouse-
anti-human vinculin antibody H-10 was used at 1:1000 (Santa Cruz).  Samples were run on a 
7.5% gel.  HRP-conjugated secondary antibody was used at 1:2000, and visualization of HRP 
used Pierce ECL kit.   
 
Mitomycin C sensitivity testing 
Mitomycin C (MMC) was resuspended in water.  Fibroblasts were plated at a density of 
1250 cells / cm2 in DMEM/10% FCS media.  The next day, media was replaced by media 
containing 0, 5, 15, 50, or 200 nM MMC.  Media was changed every 2 days for 1 week.  BCA 
kit (Pierce) was used to determine total protein concentration per well, and each cell line was 
normalized to the amount of protein present in the untreated wells.  Each treatment group 
contained 8 replicates. 
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Studies and results 
 
We set out to test our hypothesis of the role of FA proteins in reprogramming by 
generating an ideal experimental reprogramming system: an inducible Fanconi mouse.  Much of 
the variability in viral reprogramming assays is attributable to the method of reprogramming: 
when the four factors are carried by different viruses, the insertion sites and copy numbers of 
each factor vary greatly between target cells.  Additionally, the viruses insert their DNA into the 
genomes of the recipient cells, a process that may be particularly traumatic for cells with 
compromised DNA repair pathways.  With these considerations, we designed a system to 
investigate the Fanconi reprogramming defect that would minimize experimental noise and 
provide strong efficiency. 
 
Reprogrammable mouse 
The secondary reprogramming system is illustrated in Figure 4.1.  OCT4, SOX2, KLF4, 
and MYC are integrated at the COL1A1 locus under the control of a dox-inducible promoter, 
whose rtTA activator is integrated at the ROSA26 locus (174).  In every cell of this mouse, 
addition of doxycycline induces expression of the four reprogramming factors (inducible OSKM, 
iOSKM).  This system is termed "secondary" because the cells went through a pluripotent stage 
during generation of the mouse, so their subsequent reprogramming by doxycycline is their 
second pluripotent incarnation. 
We analyzed a number of experimental parameters of this system.  We found that 
reprogramming efficiency is highly dependent upon the number of copies of both the 
transcription factor cassette and the rtTA activator, with cells homozygous for both transgenes  
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Figure 4.1: Secondary reprogramming system.  (A) Two transgenes were targeted into the mouse genome.  
(B) Derivation of the secondary mouse and collection of reprogrammable MEFs. 
reprogramming much better than heterozygotes (Figure 4.2 A).  As expected, we were able to 
create iPS cells from many starting tissue types: MEFs, neonatal fibroblasts, peripheral blood, 
and keratinocytes (Figure 4.2 B).  For ease of experimentation, we decided to pursue our studies 
using fibroblasts.  To determine the best type of cell to start with, we compared reprogramming 
efficiency between MEFs and neonatal fibroblasts, as well as MEFs derived from different ages 
of embryo.  Using this system, MEFs reprogrammed significantly better than neonatal 
fibroblasts, and there was no difference between MEFs collected from embryos at e13.5 and 
e14.5 (Figure 4.2 C, D).  We investigated the effect of cell density on reprogramming efficiency, 
and found that day 3 splits of 10,000 - 35,000 cells resulted in good and not overcrowded  
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Figure 4.2, on following page: Optimization of secondary system.  (A) Effect of copy number of iOSKM and 
rtTA on reprogramming (25K split).  (B) Brightfield and Nanog-stained images of iPS colonies derived from the 
blood and keratinocytes of the secondary mouse.  (C) Comparison of reprogramming between murine embryonic 
fibroblasts (MEFs) and neonatal fibroblasts.  (D)  Comparison of reprogramming between MEFs derived from 
e13.5 and e14.5 day old embryos.  (E) Effect of split density on reprogramming, 5 ug/mL.  (F) Effect of 
doxycycline concentration on reprogramming (15K split). 
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Figure 4.2: Optimization of secondary system (Continued)
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reprogramming efficiency (Figure 4.2 E).  Finally, we found that 2 or 5 ug/mL of doxycycline 
provide the best reprogramming (Figure 4.2 F). 
 
FANCC knockout cells in secondary reprogramming 
We bred a FANCC knockout transgene into the secondary reprogramming mouse strain.  
Because homozygous FA mice show severely impaired fertility, we maintained our FANCC 
knockout mouse colonies as heterozygotes (Figure 4.3).  Murine embryonic fibroblasts (MEFs) 
from mice homozygous for the iOSKM cassette and rtTA were collected and genotyped to 
identify FANCC-/- and FANCC+/+ littermates.  These MEFs were plated and grown in 
doxycycline for three days.  On day 3 of reprogramming, they were split onto feeder cells and 
then switched into mouse embryonic stem cell media.  Reprogramming efficiency was measured 
by SSEA1 staining at day 21. 
Murine reprogramming protocols, 
including the one described here, prevent 
culture overgrowth by splitting on day 3.  
We have observed that individual MEF 
lines divide at very different rates.  While 
measuring MEF proliferation, up to a 7-
fold difference in cell number can be seen 
after only two days in culture.  Especially 
in secondary reprogramming, where every 
cell is exposed to doxycycline, a raw 
increase in the number of fibroblasts in the 
Figure 4.3: Breeding schema for Fanconi secondary 
mice.  The target cell for experimentation was iOSKM 
homozygous, rtTA homozygous, and either FANCC+/+ 
or FANCC -/-. 
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first few days of culture has the potential to distort the final number of colonies (175).  Because 
of this effect, a strong null hypothesis when investigating secondary reprogramming efficiency is 
that a sample “reprograms” with good efficiency simply because the input cells divide faster. 
One way to minimize the impact of differential fibroblast growth is to measure efficiency 
as the number of colonies per cell plated during the day 3 split.  This approach removes any 
effect on efficiency caused by three days of fibroblast growth.  Measuring colonies per day 3 
cell, however, introduces its own form of error, in that a true reprogramming enhancement or 
defect whose primary mechanism is enhancing early fibroblast growth will not be seen.  Thus 
there are two ways to measure secondary reprogramming efficiency: colonies per input cell and 
colonies per cell plated on day 3.  The former is vulnerable to swings in efficiency due to 
fibroblast growth rate, while the latter can overlook changes in efficiency caused by changes in 
growth rate.  Neither of these measures is fully informative, but by comparing the two we can 
determine whether an observed difference in secondary reprogramming efficiency is attributable 
to differential early growth rates or to an effect later in the reprogramming process.  For this 
reason, we report efficiency data as both (extrapolated) colonies per input cell and colonies per 
cell plated on day 3.  Please see the methods section for greater explanation of how the 
(extrapolated) colonies per input cell and colonies per cell plated on day 3 were calculated. 
In order to perform the day 3 efficiency analysis, the total number of cells in each 
condition was counted at the split.  This resulted in an accurate measure of fibroblast growth 
during the first three days of reprogramming, which we investigated after observing higher-than-
expected inter-experimental variability.  Interestingly, for a given cell on day 3, we could 
compare its history of growth with its future chances of reprogramming.  All MEFs were  
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Figure 4.4: Effect of early proliferation on eventual reprogramming efficiency.  Each dot represents one 
biological replicate.  
 
between passages 2 and 4 upon reprogramming.  A striking difference between WT and FA cells 
emerged from this analysis (Figure 4.4).  In the WT culture, growth rate was not strongly 
correlated with reprogramming efficiency.  But in the FA culture, the highest efficiencies were 
seen in experiments with the lowest initial growth rates, and high early growth rates were 
associated with the lowest reprogramming efficiency.  This suggests that for FANCC knockout 
cells, a recent history of active proliferation impedes the reprogramming process.  
Despite this apparent disadvantage, we did not observe a reliable defect in FANCC 
knockout MEF secondary reprogramming efficiency compared to wild-type MEFs (Figure 4.5).  
In some experiments, FA cells reprogrammed better than WT cells; in others, they performed 
more poorly.  We observed much higher levels of variability than expected from literature 
descriptions of this technique, both between experiments and between replicates.  There was no 
clear reprogramming defect in the FA cells, especially when efficiency was measured as colonies 
per cell plated on day 3 (Figure 4.5, right panels).  
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 Figure 4.5, on following page: Fanconi secondary reprogramming efficiency.  Left panels: extrapolated 
efficiency measured as colonies per input cell.  Right panels: efficiency measured as colonies per cell plated at 
the split on day 3.  (A) Compiled experimental data.  (B - F) Individual experiments. 
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 Figure 4.5: Fanconi secondary reprogramming efficiency (Continued) 
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The reprogramming proficiency of 
secondary FA cells—even in the face of 
inverted growth effects—surprised us.  
Previous publications had demonstrated a 
severe reprogramming defect in Fanconi 
cells.  Our findings led to two possible 
interpretations: first, that FANCC knockout 
in mice does not cause the same 
reprogramming defects as knockout of other 
Fanconi genes, or second, that the cause of the published FA reprogramming defect was absent 
from our system.  One such possible cause could be viral infection. 
Figure 4.6: Effect of reprogramming method on c
growth.  Total number of cells was counted three days 
after induction of reprogramming either by virus or by 
addition of doxycycline.    
ell 
Given the negative association between FA growth and reprogramming, we tested 
whether growth rates differed between secondary fibroblasts exposed to viruses or doxycycline.  
We directly compared the growth rates of WT and FA secondary MEFs three days after 
doxycycline addition or lentiviral OSKM infection (Figure 4.6).  In both WT and FA secondary 
cells, doxycycline induced significantly more proliferation than infection with OSKM lentivirus.  
Accordingly, if FA cells specifically fail viral reprogramming, it is not due to an increase in early 
proliferation. 
 
Episomal reprogramming of human samples  
Unfortunately, the FANCC-/- secondary system is unable to distinguish between the 
possible explanations for the lack of a severe reprogramming defect.  To investigate further, we 
turned to human samples.  We obtained cells from two FA patients, one with a mutation in 
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FANCD1 and the other missing FANCD2.  We reprogrammed these human cells using a non-
integrating episomal approach in normoxia and were surprised to find that by three weeks after 
nucleofection, dozens of colonies were visible on the plates from both patient samples.  Those 
from Patient 1 seemed to show better morphology, while those from Patient 2 tended to look 
more transformed.  Many colonies were picked from each patient sample, and iPS lines were 
easily established from 20/22 of the Patient 1 colonies and 3/5 of the Patient 2 colonies (Figure 
4.7 A).  The estimated reprogramming efficiency was 0.035% from Patient 1 and 0.001% from 
Patient 2.  A recent comparison study by our laboratory found the average episomal 
reprogramming efficiency from 12 non-FA lines to be about 0.015%, suggesting that Patient 1 
reprogrammed at least as well as most WT lines. 
Upon western blotting of the resulting iPS cells, lines derived from Patient 1 samples 
appeared to have restored function of the FA pathway (Figure 4.7 B).  We believe this is an 
instance of a previously described phenomenon in which mutant FA genes can recombine or 
spontaneously correct to produce a functional copy of the gene, thus rescuing the FA phenotype 
during in vitro fibroblast culture (176, 177).  Cells from Patient 2, however, maintained their FA 
identity, as evidenced by the total lack of FANCD2 protein and sensitivity of the fibroblasts to 
MMC (Figure 4.7 B and C).  We wondered whether the observed ease of reprogramming was 
due to the presence of p53 knockdown in the episomal system.  Although we were not able to 
investigate this question directly, loss of p53 has been shown to lead to highly irregular 
karyotype (172).  We established three lines of iPS cells from Patient 2 and selected one for 
further characterization, including an analysis that demonstrated a normal karyotype  
(Figure 4.7 D). 
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Figure 4.7: iPS cells derived from human FA patients.  (A) Brightfield images of iPS colonies on the 
reprogramming plate (passage 0) from both patients (40x).  Colonies on the left side of the divider successfully 
formed iPS lines; colonies on the right side of the divider did not.  (B) Western blot for FANCD2.  Heavy upper 
band demonstrates restoration of FA pathway activity in Patient 1 iPS lines.  (C) Mitomycin C sensitivity of 
fibroblasts from Patient 2 compared to WT.  (D) Karyotype of FA-iPS line derived from Patient 2. 
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We were impressed by how easily we could derive FA-iPS cells using non-integrating 
episomal reprogramming methods.  Unfortunately, obtaining patient samples is often a limiting 
factor in Fanconi anemia research, and we have been unable to obtain samples from other 
patients for investigation.  Thus while our data are provocative, they are not sufficient to 
conclude that episomal reprogramming of FA cells is definitively more efficient than viral 
reprogramming.   
In addition to the successful episomal reprogramming of a human patient line, we 
designed and generated a FANCC synthetic modified RNA that restored function of the Fanconi 
pathway in FANCC-/- human cells (See Appendix).  It is our hope that this tool, combined with 
viral and non-integrating reprogramming, will contribute to the eventual elucidation of the cause 
of the FA reprogramming defect.  Once the cause is understood, researchers will be able to 
generate patient-specific FA-iPS cells.  Eventually, these cells could be used as a source of 
autologous stem cells for Fanconi patients who do not have a matched bone marrow donor. 
 
Discussion and Future Directions 
 
The purpose and function of Fanconi anemia genes have been determined by years of in 
vitro work, and now a relatively clear picture has emerged: loss of any gene involved in the 
resolution of DNA crosslinks will result in FA.  Some clinical aspects of the disease are even 
understood on the molecular level, such as endogenous aldehyde damage to DNA and p53's role 
in hematopoietic stem cell depletion, while others such as skeletal abnormalities remain 
mysterious (178, 179).  Because bone marrow failure is one of a handful of disorders that could 
be cured by cell transplantation, there is much interest in derivation of patient-specific iPS cells.  
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However, FA patient cells appear to be resistant to reprogramming by viruses carrying OCT4, 
SOX2, KLF4, and MYC.   
Laboratories around the world have attempted to reprogram cells from human Fanconi 
anemia patients (10, 163, 180).  Only two human FA-iPS cell lines have ever been published, 
one of which carried a severely abnormal karyotype (180).  The question of why FA cells are so 
hard to reprogram has intrigued scientists: the mere demonstration that corrected patient cells—
essentially wild-type cells—could be reprogrammed was published in the journal Nature (163).  
Mueller et al. found that murine FA cells can be reprogrammed, albeit at lower efficiency than 
WT cells (180).  We attempted to generate an ideal experimental system for investigating the FA 
murine reprogramming defect: the secondary reprogrammable mouse is described as fast, 
efficient, and reliable, with no variation due to copy number differences or insertion site effects.  
The secondary murine system is touted as a low noise, high efficiency system, so we 
were disappointed to observe considerable inter-experimental variation.  When we attempted to 
identify why some of the experiments seemed to reprogram more efficiently than others, we 
noted that the fibroblast growth rate during the first three days of reprogramming varied 
significantly between cell lines and between experiments.  We were struck by the observation 
that FANCC knockout MEFs which spontaneously underwent intense proliferation 
reprogrammed more poorly than those that grew slowly.  WT reprogramming efficiency, on the 
other hand, was not correlated with fibroblast growth rate during the first few days of 
reprogramming.  We wondered whether the effect of proliferation on FA reprogramming 
efficiency could be the underlying reason for the FA defect reported in viral systems.  This 
theory would predict that viral OSKM transfection induces more proliferation than does 
activation of the secondary system.  However, we observed that secondary MEFs proliferated 
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significantly more after addition of doxycycline than they did after infection with viruses 
carrying OCT4, SOX2, KLF4, and MYC.  Thus, the published FA reprogramming in viral 
systems is not likely due to FA cells' sensitivity to proliferation.   
The effect of cellular proliferation on reprogramming is an area of intense research, and 
most studies suggest that proliferation is correlated with improved reprogramming efficiency 
(175, 181).  Our surprising observation of an inverse correlation between early growth and 
reprogramming efficiency in FA cells is particularly interesting in light of paper published by Dr. 
Jun Lu's laboratory in February of this year (182).  The authors used continuous live-cell 
imaging to study inducible reprogramming from MEFs and murine hematopoietic cells.  They 
identified a subpopulation of input cells that gave rise to nearly exclusively iPS colonies.  These 
cells were characterized by extremely rapid cell division, and thus called ultrafast cells.  Because 
most of the reprogrammed colonies were derived from ultrafast cells, the overall reprogramming 
efficiency was tightly correlated to the number of ultrafast cells in the starting sample.  This 
number could be increased by knockdown of p53, suggesting that the previously-described effect 
of p53 knockdown on reprogramming may be mediated through its effect on the ultrafast cell 
population.  This work suggests that an investigation of the cell cycle profile of day 3 
reprogramming FA cultures could provide insight in to the trend seen in Figure 4.4.   
We originally hypothesized that the FA reprogramming defect occurred because the FA 
proteins play a vital role in DNA repair during the reprogramming process.  However, this 
hypothesis was not fully borne out by our data.  When the FANCC knockout mice were bred into 
the homozygous secondary reprogramming mouse background, we were surprised to find that 
the FANCC-/- MEFs reprogrammed with nearly the same efficiency as cells from their WT 
littermates.  This unexpected finding suggested two possible alternate hypotheses: either FANCC 
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cells reprogram with better efficiency than other Fanconi anemia genotypes, or the cause of the 
published reprogramming defect was absent from our system. 
One figure in the paper from the Williams laboratory drew our consideration: the authors 
observed that although FANCC-/- cells showed a moderate reprogramming defect, FANCA-/- 
cells were more severely impaired.  This finding is surprising given the FA molecular pathway: 
FANCA and FANCC are two members of the same core protein complex, and FANCA has 
never been found to have any functions independent from FANCC (183).  The two genes are 
believed to be largely epistatic: even double knockout mice show a phenotype no more severe 
than either single knockout (184).  Additionally, of the six FA samples that our laboratory 
attempted to reprogram in 2008, two were FANCC-/- and these two samples failed 
reprogramming along with the others.  However, given the Williams lab's observation, it remains 
possible that a difference between gene function accounts for the lack of reprogramming defect 
in our secondary FANCC-/- mice.   
The other possibility is that our FA cells reprogrammed as well as WT cells because the 
cause of the published reprogramming defect was absent from our system.  A major difference 
between our system and others' was the method of OSKM expression: our secondary 
reprogramming was initiated by the simple addition of doxycycline.  All previous publications 
on FA reprogramming defects, and our lab's unpublished experience, used integrating viruses to 
introduce the four factors.  Although it is not yet known whether FA proteins are directly 
involved in viral integration, DNA repair proteins associated with the FA pathway such as 
hRad18 and Ku70 are directly involved in the integration process (168, 185, 186).  Viral 
infection may therefore affect FA cells differently than it does WT cells.   
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The data presented here are insufficient to demonstrate conclusively the cause of the 
published FA reprogramming defect.  However, given that FANCA and FANCC are largely 
epistatic in other contexts and that FA mouse cells reprogrammed well in a non-integrating 
system, we believe that integration of viruses into the genome is likely to be a contributing cause 
of the FA reprogramming defect.  This new hypothesis predicts that FA cells reprogram more 
poorly than WT cells only when reprogramming is mediated by virus.  We performed a brief 
follow-up experiment in which non-integrating episomes were used to reprogram human Fanconi 
fibroblasts.  We were indeed able to easily reprogram the cells and establish FA-iPS lines, but 
the sample size was only a single FA patient. 
This question is the most interesting future direction for this project.  To properly 
investigate, one would obtain samples from multiple patients that have different FA genotypes, 
to control for potential inter-genotype variation.  Two experiments should be performed on these 
and WT samples.  First, they should be subjected to episomal reprogramming with and without 
viral infection: one condition of each sample would be infected by a control virus such as GFP, 
and the other would not.  Reprogramming efficiency should be measured for each condition.  If 
the GFP virus negatively affects the reprogramming efficiency of the FA cells but not the WT 
cells, this would be evidence that viral infection per se impairs FA reprogramming. 
Secondly, double knockout of p53 and FA proteins has recently been shown to reduce 
Fanconi hematopoietic phenotypes (178).  A reasonable extension of this finding would suggest 
that the improvement in reprogramming efficiency we observed with the episomal system could 
be due to its p53 knockdown, not its non-integrating nature.  This hypothesis should be tested by 
direct comparison of reprogramming efficiencies between viral and episomal systems utilizing 
exactly the same genes, promoters, and 2A spacing sequences.  Preparation of these materials 
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would have to be accomplished from scratch, as there are currently no viral and episomal 
systems that utilize the same OSKM cassettes.  Once the reagents were made, however, this 
experiment would determine whether the observed facilitation in FA reprogramming efficiency 
is due to p53 knockdown or the non-integrating nature of the episomal system. 
Preparation and execution of these experiments would require additional years of work 
and expanded access to patient samples.  Therefore, they represent excellent starting points for 
the next scientist interested in the mechanisms of the FA reprogramming defect.   
 
Conclusion 
 
This project was initiated because we believed that the FA reprogramming defect 
signified a vital role for DNA repair in the reprogramming process.  The absence of a severe 
reprogramming defect in our secondary system suggests that the Fanconi DNA repair pathway is 
not, in fact, required for efficient reprogramming.  Instead, certain FA proteins may be 
important, or the FA pathway may be called upon to aid cellular recovery from viral integration.  
We hope that the work described in this chapter will contribute to more thorough understanding 
of the Fanconi pathway in the reprogramming process. 
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Chapter 5: Discussion and Future Directions of the Field 
 
Genetic diseases must be studied in the affected cell type 
 
Cellular identity is often invoked in cancer research, but much less frequently in 
discussion of genetic disorders.  The mutation is present in every cell of the body, so genetic 
diseases are often investigated in patients' easy-to-access blood or skin cells.  But these systems 
do not take into account the effect of cellular identity on gene function and cellular phenotype, so 
they cannot provide the most accurate information on genetic diseases. 
A mutation in a given gene will cause vastly different effects in different cell types: the 
gene's expression levels may be different, it may be crucial or dispensable, and there may be 
other proteins present that amplify or negate its effects.  This was underscored by the three 
Dravet syndrome papers described above, where the true effect of a sodium channel mutation 
was completely misunderstood until it was finally studied in neurons (145-147).  The same effect 
can be seen even more clearly in the mitochondrial field: when fused to wild-type nuclei with 
different cellular identities, a single mutant mtDNA genome produces very different phenotypes 
(102, 103).   
iPS cell-based models have the potential to solve this problem.  If scientists can create a 
differentiation protocol for the type of cell affected by the disease, the mutation can be studied in 
the proper cellular context.  This may not only lead to a better understanding of how the mutation 
causes symptoms, but also suggest novel mechanism-based approaches to therapies. 
We employed cellular identity transformations to create the cell types affected by various 
genetic diseases.  This dissertation depicts the progression towards reprogramming models of 
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three genetic disorders: Pearson syndrome, ring 14 syndrome, and Fanconi anemia.  Each of 
these diseases is at a different stage of its research lifecycle: our Pearson syndrome iPS cells 
were the first published pluripotent cells to carry deleted mtDNA and we identified a Pearson 
syndrome-specific phenotype in blood cells; we created iPS cells carrying ring chromosome 14 
and generated the first neural cells from a ring 14 patient available for study; we reprogrammed 
mouse and human Fanconi anemia cells using non-integrating approaches and observed 
surprisingly robust efficiency.  These research advances demonstrate the power of cellular 
identity manipulation for research on genetic diseases.   
 
Genetic, epigenetic, and environmental factors control cellular identity in vivo 
 
Unicellular organisms all have a single goal, to survive long enough to reproduce.  The 
difference between these basic organisms and multicellular creatures like humans is simple: in 
complex organisms, different cells play different roles.  A neuron will express neuronal genes 
but will never express liver-specific genes; a melanocyte will produce melanin after exposure to 
UV light but a fibroblast will not.  These cell types all contain the same genetic sequence, but the 
differences in their responses are determined by which regions of the DNA are accessible to 
transcription.  In complex organisms, the epigenome maintains cellular identity by carefully 
allowing certain genes and non-coding RNAs to be expressed in a given cell type, while 
simultaneously blocking access to other regions of the genome.   
As a human zygote cleaves, and through subsequent rounds of cell division develops into 
a complex organism, cells transition inexorably from one identity to another.  Gene expression 
from a single genome evolves and adapts via a carefully choreographed and directed set of 
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inductive and selective events, until 
lineages become segregated and tissue 
fates are determined.  Evolution has 
invested heavily in maintaining and 
restricting cellular identities in mammals: 
once a mammalian cell has progressed 
through its natural developmental 
transitions, its final specialized state is 
sustained by a loss of self-renewal and 
inevitable senescence.   
Figure 5.1: Cellular identity transformations.  Blue are 
in vivo transformations; red are the corresponding in vitro 
transformations.   
Occasionally, genetic, epigenetic, or environmental changes can cause cell identity to 
change.  In vivo cellular identity changes are called dysplasia (Figure 5.1).  Dysplasia often leads 
to malignancy, in which cellular identities have changed so completely that the cancer cells 
behave like single-celled organisms, surviving and reproducing regardless of the needs of the 
whole person.   
The most common cause of dysplasia is genetic mutation.  Cancer-causing mutations 
often manipulate cellular identity by affecting genes related to self-renewal and senescence 
(187).  For example, when normal hematopoietic precursors acquire mutations that allow them to 
self-renew, they are quickly transformed into leukemic stem cells (188).   
Epigenetic alterations can lead to dysplasia by changing the transcriptional accessibility 
of certain genes, especially those related to metastasis.  For example, hypomethylation of the 
pro-metastasis gene SNCG has been shown to play a causal role in metastasis of breast and 
ovarian tumors (189). 
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More rarely, transformation of cellular identity is brought about as a reaction to extreme 
environmental conditions.  For example, metaplasia and subsequent adenocarcinoma can occur 
when esophogeal tissue is repeatedly exposed to stomach acid (190).  Likewise, in January of 
this year, two surprising papers showed the conversion of somatic cells into pluripotent cells by 
transient exposure to acidic conditions (191, 192).  Although their findings may or may not be 
repeated by other laboratories, the papers sparked much scientific discussion of the influence that 
a cell's environment—pH, physical stresses, oxygen tension, hyperglycemia, toxins, UV 
exposure, or nutrient deprivation—can have on its identity. 
Researchers are now co-opting these three methods of cellular identity transformation to 
reprogram cells to pluripotency.  Reprogramming provides the cell with extra copies of genes 
that encourage self-renewal and prevent senescence.  These factors erase the old epigenetic 
cellular identity and establish a pluripotency epigenetic network in its place.  Finally, a few days 
into the reprogramming process, the cellular environment is adjusted by changing the media to 
fit the nutritional and signaling requirements of pluripotent stem cells.  This was the recipe for 
cellular identity manipulation that Dr. Yamanaka created. 
 
The future of iPS cell-based modeling: complex disorders 
 
The same three factors that control cellular identity can also be the underlying causes of 
illness.  Genetic diseases occur when a DNA mutation causes a clinical phenotype, such as 
Pearson syndrome, ring 14 syndrome, or Fanconi anemia.  Epigenetic disorders occur from 
improper regulation of genes, such as imprinting syndromes.  Environmental ailments are caused 
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by outside forces, such as a skin burn caused by boiling water.  But most disorders do not fall 
neatly into one of these three categories.   
The vast majority of disorders affecting the human population have genetic, epigenetic, 
and environmental predispositions.  For example, identical twins are often discordant for 
complex diseases such as schizophrenia, type II diabetes, or autism (193).  Between monozygotic 
twins, the difference in phenotype cannot be genetic so must be caused by the different 
environments the twins' cells have experienced as they aged and the resulting changes in 
epigenetics and cellular behavior.  Additionally, many complex disorders manifest at late ages: 
early-twenties for bipolar disorder, mid-seventies for Alzheimer's disease.  Stochastic epigenetic 
and environmental events that occur over decades of life can profoundly affect cellular function, 
creating a permissive backdrop upon which disease phenotypes can be expressed (194).   
During reprogramming of somatic cells to pluripotency, epigenetic histories are erased 
and standard tissue culture conditions normalize all environmental differences.  Of the genetic, 
environmental, and epigenetic variation that leads to complex disease, the only source of 
variation likely to be faithfully maintained in iPS cell lines is the genetic variation.  In order to 
create a complete in vitro model of complex disorders, scientists must find a way to induce the 
epigenetic and environmental factors in their system.   
In a notable attempt to induce complex disease phenotypes by mimicking aged cells, 
researchers from the Sloan-Kettering Institute recently overexpressed a truncated version of the 
gene LMNA in fibroblasts and neurons (195).  This mutant protein, known as PROGERIN, is 
responsible for the aging syndrome progeria.  The researchers noted that after PROGERIN 
expression, cell nuclei, gene expression, and methylation markers were similar to those seen in 
cells from elderly individuals, so they wondered whether this "aged" cellular backdrop could 
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allow complex disease phenotypes to manifest.  They found that in cells receiving PROGERIN, 
but not cells receiving GFP, genetic mutations associated with Parkinson's disease caused 
appreciable cellular PD phenotypes.  These included reduced dendrite length and a dramatic 
reduction in the number of tyrosine hydroxylase positive cells produced in vivo.  Although this 
paper did not perform any specific or measured manipulations of epigenetics or environmental 
stimuli to induce PD, it is a groundbreaking example of how manipulating the cellular 
environment can affect the penetrance of a genetic disease predisposition.   
To model a complex disorder even more accurately, researchers should induce the 
specific epigenetic and environmental events that lead to expression of the disease phenotype.  
For example, in Barrett's esophagus, exposure to acidic pH induces esophogeal cells to take on 
characteristics of the lower gut.  Genetic predisposition, gene regulation, and acid exposure all 
contribute to the appearance of Barrett's esophagus (heritability is estimated at 0.35) (196).  A 
reprogramming-based model of this condition would start by differentiating patient-specific iPS 
cells into esophogeal cells, and then model the disease by exposing them to repeated bouts of 
acid.  In this case the genetic component would include the individual's predisposition to 
metaplasia, and the cells' epigenomes would reflect the previous acid exposures.  Finally, 
duration and intensity of the acidic solution would affect severity of the resulting phenotype.  A 
reprogramming-based model of Barrett's esophagus would need to take all three of these factors 
into account in order to reproduce a physiologically accurate in vitro model.  This leads to a 
well-controlled triad experimental model: as long as two of the three variables are held constant, 
the third can be manipulated to test hypotheses about metaplasia and the disease mechanism.  
These types of experiments will provide a much-needed tool to investigate the effects of 
epigenetic manipulations on cellular disease states.  They will also be useful for teasing apart 
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genotype by environment or genotype by epigenome effects, because the behavior of cells with 
various genetic backgrounds can be directly compared.   
Our recent appreciation for the plasticity of cellular identity makes this area one of the 
most exciting topics in modern biology.  Dr. Yamanaka’s seminal publication has compelled a 
new and creative open-mindedness about cellular identity, and paved the way for the 
development of iPS cell-based disease models, drug screens, and transplantation.  Full realization 
of the promise of cellular therapies is still on the horizon, but use of reprogramming technology 
for disease modeling and drug testing has already begun to show us the possibilities.   
 
Conclusion 
 
Medical genetics has advanced to the point where Pearson syndrome, ring 14 syndrome, 
and Fanconi anemia are likely to be diagnosed at a young age.  An accurate diagnosis is a 
blessing to families, as it gives them information about their child's probable future and allows 
them to reach out to other families for support.  But along with these diagnoses comes bad news: 
their child's disease has no treatment.   
Our laboratory's long-term goal is to create models that reveal disease mechanisms and 
suggest novel therapeutic approaches to rare genetic disorders.  In this dissertation, we describe 
work towards this goal for three diseases.  We generated the iPS cells that carry a mtDNA 
deletion and identified a pathognomonic signature of Pearson syndrome in erythroid progenitors 
bearing the mutation.  For the same child, we also derived a patient-specific iPS line that was 
completely free of disease, a technique that could be used in the future to create cells for 
transplantation.  In ring 14 syndrome, the inability to study the ring chromosome in neurons has 
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been an insurmountable hurdle for researchers.  We reprogrammed cells from patients with ring 
chromosome 14 and differentiated the resulting iPS cells down a neuronal pathway.  The 
resulting cells are the first neural cells from a ring 14 patient available for investigation.  Even 
better, since they come from a pluripotent stem cell line, more neural cells can be generated at 
will.  Finally, we reprogrammed mouse and human Fanconi anemia cells using non-integrating 
methods.  The secondary FA mouse cells reprogrammed nearly as well as the WT cells, and our 
human sample reprogrammed easily with episomes.  These surprisingly robust findings lead us 
to believe that the FA pathway is not as indispensible to the reprogramming process as we had 
hypothesized, and suggest more experiments to investigate how FA cells respond to viral 
infection.   
All of this work has taken advantage of cellular identity changes.  By providing 
exogenous transcription factors and manipulating the environmental conditions, we have been 
able to generate pluripotent cells and direct their differentiation into hematopoietic and neuronal 
lineages.  Dr. Yamanaka's breakthrough paper was published less than ten years ago, and its 
rewards have already been rich.  In the next ten years, hopefully it will bear fruit for the families 
expectantly waiting on new treatment approaches and therapeutics.   
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Appendix: mRNA Transfection 
 
Reprogramming can be accomplished by many approaches.  Early publications used 
retroviruses, which quickly gave way to more versatile lentiviral vectors (197-199).  But both of 
these systems shared a fatal flaw: the reprogramming factors integrated into the host genome.  
Low titer lentiviral systems with floxed monovector cassettes came close to resolving this issue 
by removing the transcription factors, but they still left behind a genetic scar (200, 201).  Such a 
scar is unlikely to be approved for clinical-grade cells, so much work has gone into finding other 
reprogramming methods that do not involve permanent genetic modification.  
Laboratories have reprogrammed cells using protein transfection, mRNA transfection, 
episomal expression, and forms of non-integrating viruses such as AAV and Sendai (202-211).  
Multiple laboratories have reported partial success using chemicals to supplement the 
reprogramming process, and a few recent papers report that cellular stress can reprogram cells 
under rare circumstances (191, 192, 212, 213).   
At the time that our FANCC-/- secondary reprogramming mouse system was in 
development, reprogramming via mRNA transfection had just been published.  The reported 
efficiency was an astoundingly high 4%.  We suspected that the Fanconi reprogramming defect 
was not an absolute barrier, but rather one of efficiency, so we were quite interested in utilizing 
the mRNA reprogramming platform to investigate the FA reprogramming defect. 
In order to obtain such high efficiencies, Dr. Derek Rossi's group had optimized a very 
complex protocol.  The mRNA was in vitro transcribed with multiple modifications to prevent 
activating the cellular immune response, and then transfected into the reprogramming cells for 
four hours each day (202).  Anticipating FANCC-/- reprogramming experiments, we set out to 
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design and create a modified mRNA encoding a rescue copy of FANCC.  We began with the 
human FANCC ORF, and added a Kozak sequence immediately 5' of its translational start site, 
along with 5' and 3' UTR sequence, and then cloned this construct into a plasmid.  To generate 
the DNA sequence of the complete mRNA (5' UTR, Kozak, ORF, 3' UTR, and poly-A tail), we 
performed PCR off of the template using a primer encoding a poly-A tail.  This template was 
then used for in vitro transcription, including 5-methyl cytidine and pseudouridine as described 
in Warren et al. for reduced immune reaction. 
The one part of an mRNA transcript that cannot easily be added is the 5' guanine cap.  
This cap is a specially-modified guanine base, and has to be encoded into the RNA during 
transcription.  In order to make sure that some of the resulting mRNA molecules carried the 5' 
cap, we included these di-guanosine cap analogs at a 4:1 ratio with normal guanine in the 
transcription mix.  The analogs cannot be incorporated into a growing mRNA chain, so guanine 
was the limiting reagent for mRNA synthesis (214).  The 4:1 ratio ensured that about 80% of the 
resulting mRNA molecules carried a 5' cap.  The resulting mix of mRNA was treated with a 
phosphotase to remove the 20% of free 5' phosphates, as these can cause immune response in the 
cells (202).   
We obtained late-passage Fanconi patient fibroblasts from a cell repository to test 
whether our new FANCC mRNA could rescue the Fanconi pathway in human cells.  When the 
FA pathway is active, the FANCD2 protein becomes ubiquitinated.  On western blots, it appears 
as a heavier band, called FANCD2-L.  Upon addition of hydroxyurea, in WT cells the FA 
pathway is activated and so the long:short ratio increases.  We transfected the FANCC mRNA 
into FANCC-/- human fibroblasts daily and exposed some of the cells to hydroxyurea.  As seen 
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in Figure App.1, transfection of the FANCC mRNA effectively rescued activity of the FA 
pathway in human Fanconi anemia cells. 
In the paper published by the Rossi group, a constant amount of reprogramming mRNA 
was transfected daily, while the number of cells grew exponentially.  At the time, it was not 
known how the ratio of mRNA micrograms to cell number affected transfection.  On one hand, it 
could be that all mRNA molecules always entered the cells, such that any variation in cell 
number would strongly affect the number of mRNA molecules received by each cell.  On the 
other, it could be that mRNA molecules were present in such excess that the cell number was 
irrelevant to the per-cell dosage—or anywhere in between these two extremes.  We set out to 
quantify this phenomenon. 
Fibroblasts were plated at four different densities and transfected with various amounts of 
in vitro transcribed, low-immunogenic mRNA coding for GFP.  FACS analysis was used to 
measure mean fluorescence intensity (MFI; a proxy for the number of GFP mRNA molecules 
received by the cell), the raw number of GFP positive cells, and the percentage of cells that were 
GFP positive (Figure App.2).   
Figure App.1: Western blot showing mRNA functional correction of FA pathway.  Each panel is a 
condition, with or without addition of hydroxyurea (HU).  FANCC knockout cells (FC) do not have the long 
form of FANCD2.  FANCC knockout cells plus the FANCC mRNA show the long form.   
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Larger quantities of mRNA resulted in more mRNA molecules per cell and more cells 
transfected (Figure App.2 A and B).  Surprisingly, at the highest cell density, 160 ng mRNA was 
required to achieve the same percentage GFP positive cells as the lowest density shows with 20 
ng mRNA (Figure App.2 C).  This suggests that the percentage of cells that receive mRNA per 
RNA nanogram decreases strongly with increasing cell numbers (Figure App.2 D).   
Interestingly, at any given level of RNA input, higher numbers of cells result in lower 
MFI (Figure App.2 E).  This demonstrates that higher cellular densities cause each cell to receive 
fewer copies of the mRNA molecule.  Finally, we also observed that at the lowest amount of 
RNA, there was no difference in the number of GFP positive cells between densities: 20 ng of 
RNA causes about 20,000 cells to become fluorescent, and no more (Figure App.2 F).  This 
suggests that 1,000 cells is the upper limit of the number of cells that can become fluorescent 
from 1 nanogram of mRNA. 
Our conclusion from this analysis is that the amount of mRNA received by a cell varies 
greatly depending on the cell density.  Thus, in order to maintain a constant level of mRNA 
transfection during reprogramming, the total amount of mRNA added should increase with cell 
numbers. 
In addition to transfection of mRNA into fibroblasts, we investigated transfection of 
modified mRNA into human pluripotent cells.  Specifically, we wondered whether mRNA 
transfection would be more efficient in iPS cells grown on murine feeder cells or cultured on 
matrigel.  We transfected human iPS cells with varying amounts of modified GFP mRNA, as 
described above.  As can be seen in Figure App.3, iPS cells grown on matrigel proved to be far 
easier to transfect than those grown on MEFs.   
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 Figure App.2, on following page: Characterization of cell density effect on mRNA transfection.  (A) Effect 
of increasing mRNA concentrations on mean fluorescence intensity (proxy for mRNA copies per cell).  (B) 
Effect of increasing mRNA concentrations on percentage of transfected cells.  (C) Effect of cell density on 
percentage of transfected cells.  (D) Effect of cell density on "bang for your buck," the percentage fluorescent 
cells acquired per ng of mRNA.  (E) Inverse relationship of cell density and mean fluorescence intensity, 
regardless of mRNA concentration.  (F) Effect of cell density on the absolute number of transfected cells. 
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Figure App.2: Characterization of cell density effect on mRNA transfection (Continued) 
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 We attempted to reprogram cells using mRNA multiple times.  Unfortunately, our 
laboratory and many others found the procedure highly variable.  Multiple crucial reagents were 
subject to inter-lot variability, and shortage of key components of the in vitro transcription 
reaction cut short reprogramming attempts.  Our laboratory and the Boston Children's Hospital 
stem cell core have since concluded that mRNA is a hit-or-miss reprogramming method: about 
one in three tries is highly successful, but two out of three attempts fail entirely.  Given the 
variable reprogramming efficiency inherent in this approach, we decided it was not a good 
system for pursuing investigations of Fanconi reprogramming efficiency. 
 
Figure App.3: Transfection of mRNA into human iPS colonies.  (A) Comparison of mRNA transfection into 
iPS cells grown on matrigel and MEFs.  (B) Combined brightfield and fluorescent image of 1 ug of GFP mRNA 
transfected into iPS cells grown on Matrigel.  (C) Combined brightfield and fluorescent image of 1 ug of GFP 
mRNA transfected into iPS cells grown on MEFs. 
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